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Ewing sarcoma (ES) are characterized in 85% of cases by the expression of the oncogenic fusion 
protein EWS-FLI1 which results from the fusion of two genes, EWS and FLI1, upon chromosomal 
translocation. While FLI1 is an ETS transcription factor, EWS belongs to the evolutionarily 
conserved FET family of RNA-binding proteins. So far, functional studies of oncogenic EWS fusion 
proteins have concentrated on their presumed role as aberrant ETS transcription factors. 
However, chimeric FET proteins are usually co-expressed with their intact counterparts and 
previous protein interaction studies have shown that EWS and EWS-FLI1 interact with each 
other. Therefore, it is possible that functional interference with normal EWS function accounts 
for part of the oncogenic activities of EWS-FLI1. However, the role of EWS in post-transcriptional 
and transcriptional gene regulation is poorly defined. Since FET proteins associate with a number 
of RNA processing factors, we investigated the influence of modulated EWS expression on 
genome wide transcript expression and exon composition in ES cell lines using Affymetrix HuEx-
1.0stv2 arrays. For that purpose, we established two cellular model systems: a unique ES cell line 
lacking endogenous EWS was studied upon stable restoration and re-knockdown of EWS 
expression (restoration model), and an ES cell line with stable EWS knockdown was analyzed 
upon inducible RNAi-mediated EWS-FLI1 suppression (knockdown model).  
Regarding differential expression of whole transcripts, a number of genes with expression level 
variations upon modulated EWS expression were identified in both cellular systems. Differential 
gene expression in the presence and absence of EWS might be explained by two models of 
either functional competition or functional interaction between EWS and the fusion gene, and 
genes from the overlap between the two data sets were classified accordingly depending on 
their EWS and EWS-FLI1 dependent expression patterns. 5´-RACE PCR experiments excluded the 
possibility of EWS dependent alternative transcription start site selection as a potential cause of 
altered transcript stability to account for the observed differential RNA expression effect.  
In addition, we found significant differences in exon composition of genes in each of the two 
cellular systems, but almost no overlap between the two models. The observed alternative exon 
composition patterns were verified by RT-qPCR of candidate genes.  
The phenotypic relevance of EWS expression in ES cells was examined involving two different 
functional assays. EWS expression was found to improve anchorage-independent growth in soft 
agar colony formation assays while no significant effect could be detected concerning 
anchorage-dependent growth in proliferation assays.  
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Taken together, the results described in this thesis are in line with published evidence for an 
involvement of EWS in transcriptional and post-transcriptional regulation. However, the 
differences detected between the two cellular model systems emphasize dependence of EWS 






Ewing Sarkome (ES) sind in 85% der Fälle durch das onkogene Fusionsprotein EWS-FLI1 
charakterisiert. Dieses entsteht durch die Fusion zweier Gene, EWS und FLI1, auf Grund einer 
chromosomalen Translokation. Während FLI1 ein ETS Transkriptionsfaktor ist, gehört EWS zur 
evolutionär konservierten FET Familie der RNA-bindenden Proteine. Bislang haben sich 
funktionelle Studien der onkogenen EWS-Fusionsproteine immer auf deren mutmaßliche Rolle 
als veränderte ETS Transkriptionsfaktoren bezogen. Allerdings werden chimäre FET-Proteine 
normalerweise gemeinsam mit ihren intakten Gegenstücken exprimiert und Proteininteraktions-
Studien haben gezeigt, dass EWS und EWS-FLI1 miteinander interagieren. Folglich ist es denkbar, 
dass ein Teil der onkogenen Aktivität von EWS-FLI1 in der funktionellen Interferenz mit der 
normalen Funktion von EWS besteht. Die exakte Rolle von EWS in der transkriptionellen und 
post-transkriptionellen Genregulation ist jedoch bislang nicht gut definiert. Da FET Proteine mit 
einer großen Anzahl RNA-Prozessierungsfaktoren assoziiert sind, wurde im Rahmen dieser Arbeit 
der Einfluss modulierter EWS-Expression sowohl auf die Genexpression als auch die Exon-
Zusammensetzung von Transkripten in ES Zelllinien mittels Affymetrix HuEx-1.0stv2 Arrays 
untersucht. Zu diesem Zweck wurden zwei verschiedene zelluläre Modelle etabliert: In einer 
einzigartigen ES Zelllinie ohne endogenes EWS wurde stabile EWS-Expression wiederhergestellt 
(Wiederherstellungs-Modell). Eine andere ES Zelllinie wurde nach stabiler Stilllegung von EWS 
und induzierbarer, RNAi-vermittelter Suppression von EWS-FLI1 untersucht (Suppressions-
Modell).  
Betreffend differenzieller Expression ganzer Transkripte, konnten mehrere Gene mit EWS-
abhängiger Variation des Expressions-Niveaus in beiden zellulären Systemen identifiziert 
werden. Die differenziellen Genexpressionsmuster lassen sich durch zwei Modelle funktioneller 
Konkurrenz bzw. Interaktion zwischen EWS und dem Fusionsprotein erklären. Die Gene aus der 
Überschneidungsmenge der beiden zellulären Modelle konnten dementsprechend anhand ihrer 
EWS- und EWS-FLI1-abhängigen Expressionsmuster klassifiziert werden. Mittels 5‘-RACE PCR 
Experimenten wurde die Möglichkeit alternativer Transkriptionsstartpunkt-Selektion in 
Abhängigkeit von EWS als möglicher Grund veränderter Transkriptstabilität, die die 
beobachteten differenziellen RNA-Niveaus verursacht, ausgeschlossen.  
Außerdem konnten signifikante Unterschiede in der Exon-Zusammensetzung mehrerer Gene in 
beiden zellulären Modellen festgestellt werden. Jedoch war keine Überlappung der beiden 
Datensätze feststellbar. Diese beobachteten alternativen Exon-Zusammensetzungen konnten 
mit Hilfe von RT-qPCR verifiziert werden.  
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Die phänotypische Relevanz von EWS in ES Zellen wurde anhand zweier verschiedener 
funktioneller Tests untersucht. In Soft-Agar Colony Assays konnte gezeigt werden, dass EWS die 
Oberflächen-unabhängige Koloniebildung fördert. Proliferations-Versuche hingegen zeigten, 
dass EWS keinen Effekt auf das Oberflächen-abhängige Zellwachstum hat.  
Zusammengefasst unterstützen die hier beschriebenen Resultate bereits veröffentlichte 
Hinweise für eine Beteiligung von EWS an transkriptioneller und post-transkriptioneller 
Genregulation. Die beobachteten Unterschiede zwischen den beiden untersuchten Zellmodellen 
unterstreichen aber den Einfluss des zellulären Hintergrundes auf die EWS Funktion und dessen 






1.1 The FET Protein Family 
Since the identification of EWS as the gene product of the Ewing sarcoma breakpoint region 1 
(EWSR1) by Delattre et al. in 1992 (Delattre, Zucman et al. 1992) three more proteins have been 
identified, which form an evolutionarily conserved family of putative RNA-binding proteins: 
FUS/TLS/Pigpen/hnRNP P2 (Crozat, Aman et al. 1993; Rabbitts, Forster et al. 1993; Zinszner, 
Albalat et al. 1994; Alliegro and Alliegro 1996) and TAF15/hTAFII68/TAF2N/RPB56 (Bertolotti, 
Lutz et al. 1996; Hackl and Luhrmann 1996) as well as the Drosophila ortholog Cabeza/SARFH 
(sarcoma-associated RNA-binding fly homolog) (Immanuel, Zinszner et al. 1995; Stolow and 
Haynes 1995). All members of this protein family, which is generally referred to as FET (FUS/TLS, 
EWS, TAF15) family of proteins, are structurally and functionally related and share extensive 






descriptions of a new subtype of bone sarcoma characterized by the BCOR-CCNB3 gene fusion 
suggest the FET protein family to be still expanding (Pierron, Tirode et al. 2012). The proteins are 
almost ubiquitously expressed and mostly localized to the nucleus (Andersson, Stahlberg et al. 
2008). Due to genomic translocations, all known FET proteins have been found to be fused to 
transcription factors thereby contributing to the genesis of a variety of human sarcomas and 
acute leukemias. The resulting fusion proteins function as aberrant transcription factors which is 
the reason for most mechanistic studies so far to concentrate on the identification of 
downstream target genes. However, there is evidence for an interaction between EWS and its 
oncogenic derivative EWS-FLI1 (Spahn, Siligan et al. 2003) which supports the hypothesis that 
the oncogenic fusion proteins exert a dominant-negative effect on normal FET protein functions. 
Furthermore, FET proteins were found to interact with each other (Pahlich, Quero et al. 2009) 
implicating them to be engaged in the same protein complexes and cellular processes [for 
review see (Law, Cann et al. 2006; Tan and Manley 2009; Kovar 2011)] although their precise 
functions still remain poorly characterised. Thus, the following chapter will give a detailed 
summary of the current scientific knowledge concerning the biologic role of FET family proteins. 
Figure 1. Comparison of amino 
acid similarity and identity over 
the whole protein and within the 
RBD for FUS/TLS, EWS and TAF15. 
(from Tan and Manley, 2009)  
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1.1.1 Functional Motifs 
The FET protein family is defined by akin composition of functional domains (figure2): The 
amino-terminus or activation domain (AD) is enriched for serine, tyrosine, glycine, and glutamine 
(SYGQ) residues and functions as potent transcriptional activation domain (May, Lessnick et al. 
1993; Prasad, Ouchida et al. 1994; Zinszner, Albalat et al. 1994; Bertolotti, Bell et al. 1999) when 
fused to the DNA-binding domain of a transcription factor as a result of genomic translocation. 
Despite similar glutamine-rich elements observed in various transcription factors, their function 







The carboxy-terminus of FET proteins contains one RNA-binding domain (RBD) also referred to 
as RNA-recognition motif (RRM), comprising approximately 80-90 amino acids, with three 
adjoining arginine-glycine-glycine (RGG)-boxes (Burd and Dreyfuss 1994), one C2/C2 zinc finger 
motif (ZF) (Morohoshi, Ootsuka et al. 1998) and a conserved nuclear import and retention signal 
(C-NLS). The basic C-NLS comprises 18 amino acid residues (PGKMDKGEHRQERRDRPY) and 
shares no homology to other known NLS sequences but seems to be highly conserved within the 
FET family of proteins (Zakaryan and Gehring 2006). 
RGG-boxes are defined as closely spaced arginine-glycine-glycine repeats separated by other, 
often aromatic, amino acids. RGG-boxes usually occur in combination with other types of RNA-
binding domains (Kiledjian and Dreyfuss 1992) and are thought to facilitate binding since their 
RNA binding is relatively sequence unspecific (Burd and Dreyfuss 1994). 
The zinc-finger domain is the eponymous structural characteristic of a family of DNA-binding 
proteins but it has also been found in a number of RNA-binding proteins, e.g. TFIIIA and RNA-
polymerases, without there being an obvious difference in the amino acid composition between 
predominantly DNA and RNA binding zinc fingers (Theunissen, Rudt et al. 1992). C2/C2 zinc 
fingers similar to the one present in FET family proteins have been observed in ribosomal as well 
as pre-rRNA-processing proteins (Chan, Suzuki et al. 1993; Hess, Stanford et al. 1994). 
Figure 2. Domain structure 
of FET and Cabeza/SARF 
proteins. AD - Activation 
domain, RGG boxes, RBD - 
RNA binding domain, ZF -  
C2/C2 zinc finger domain, 
arrowheads depict 
sarcoma breakpoint 




The high level of conservation between the members of the FET family of proteins is most 
apparent in the RBD (Tan and Manley 2009). RBDs consist of four antiparallel β-strands and two 
perpendicularly oriented α-helices (Burd and Dreyfuss 1994). Like in other RNA-binding proteins 
the FET-RBD contains two sub-domains, the octameric RNP-1 and the hexameric RNP-2, which 
are highly conserved and locate to the two central β-strands, β1 and β3. The charged and 
aromatic side chains of RNP-1 and RNP-2 are exposed and are thought to make contact with 
bound RNA molecules via hydrogen bonds and ring stacking. However, the FET-RBD differs from 
the typical RBD in two considerable ways: First, the highly conserved aromatic residue at 
position +3 of RNP-1 is substituted for a negatively charged amino acid, namely glutamic or 
aspartic acid. Second, loop 2, which is usually 3-4 amino acids long, is extended and contains 12 
amino acids in FET proteins (Stolow and Haynes 1995; Hackl and Luhrmann 1996). 
There are some structural variations between the FET protein family members, albeit their 
highly analogous domain composition. The amino-terminus of EWS is rich in proline and 
threonine and encompasses multiple degenerate hexapeptide repeats with the consensus 
SYGQQS, where the tyrosine at the second position is absolutely and the glutamine at the fourth 
position is highly conserved (Feng and Lee 2001; Ng, Potikyan et al. 2007). This region shares 
40% homology to the carboxy-terminus of the RNA polymerase II largest subunit and its high 
content of glutamine and proline is reminiscent of activation domains of various transcription 
factors (Delattre, Zucman et al. 1992). Systematic computational as well as mutational analysis 
revealed this region to be intrinsically disordered and the aromatic side chains of the conserved 
tyrosine residues to be required for the transactivating properties of the AD (Ng, Potikyan et al. 
2007). In addition, one IQ domain is localized at the carboxy-terminal end of the EWS amino-
terminal domain (Deloulme, Prichard et al. 1997). This domain was found to bind to the splicing 
factor/transcriptional repressor SF1/ZFM1 [(Zhang, Paley et al. 1998) see figure3]. 
 
  
Figure 3. Protein structure of EWS. NTD - amino-terminal domain; CTD - carboxy-terminal 
domain; R7BS - RPB7-binding domain; DHR – Degenerate hexapeptide repeats; ZFM1(IQ) - IQ 
domain binding to ZMF1; RGG 1, 2, 3 – Arginine/Glycin/Glycin-boxes 1, 2, 3; RRM – RNA 
recognition motif; Z – Zinc finger domain; NLS – Nuclear localisation signal; aa – amino acid; 
EAD – EWS activation domain; RBD – RNA-binding domain; Fusion region – Region disrupted by 
the fusion to transcription factor moieties upon EWS-rearrangement. (from Kovar, 2011) 
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In TAF15, the RGG-boxes are not as closely spaced as in the other two FET proteins and overlap 
with 17 perfect and 3 imperfect GGYGGDR-repeats (Burd and Dreyfuss 1994; Bertolotti, Lutz et 
al. 1996; Morohoshi, Arai et al. 1996). Whether this protein motif plays a role in RNA-binding or 
not remains to be investigated. 
The Drosophila melanogaster ortholog SARFH/Cabeza shares homology to the carboxy-terminus 
of the remaining FET proteins which is most apparent in the RRM. However, there is very limited 
sequence identity in the amino-terminal region (Immanuel, Zinszner et al. 1995; Stolow and 
Haynes 1995). Nonetheless, the amino-terminus of SARFH/Cabeza contributes to the 
transformation of NIH3T3 cells when fused to CHOP instead of TLS (or EWS), although it does not 
activate transcription in neither mammalian nor Drosophila cells (Immanuel, Zinszner et al. 
1995). 
 
1.1.2 Regulation of FET proteins 
FET proteins contain various sites for post-translational modifications such as phosphorylation 
and arginine methylation (Tan and Manley 2009). Post-translational modifications at or near the 
RBD or RGG motifs are thought to affect protein stability, RNA- or DNA-binding, protein-protein 
interactions or subcellular localization (Burd and Dreyfuss 1994). 
 
1.1.2.1 Phosphorylation 
EWS and FUS/TLS are targeted by a number of Ser/Thr kinases. ATM, a member of the PIKK 
family of protein kinases, phosphorylates FUS/TLS - but not FUS-CHOP – at Ser 42 in vivo upon 
induction of DNA double-strand breaks (Gardiner, Toth et al. 2008). Likewise, EWS and EWS-FLI1 
are phosphorylated at Thr 79 by JNK and p38α/p38β MAPK, respectively, in response to DNA 
damage. In comparison to the strong phosphorylation after DNA damage, the same residue is 
weakly phosphorylated by ERK1 and ERK2 after mitogen induction (Klevernic, Morton et al. 
2009). 
Additionally, the EWS-IQ domain is phosphorylated at Ser 266 by PKC which prevents binding of 
EWS to RNA. This suggests that the amino-terminal domain of EWS is involved in the regulation 
of the binding activity of its carboxy-terminal domain (Deloulme, Prichard et al. 1997). FUS/TLS 
was found to be another substrate of PKC phosphorylated at Ser 256 (Perrotti, Bonatti et al. 
1998) which prevents it from proteasome-mediated degradation (Perrotti, Iervolino et al. 2000). 
Moreover, FUS/TLS and TAF15 have been found substrates for Tyr phosphorylation. FUS/TLS is 
tyrosine phosphorylated in FGF-, EGF- and PDGF-stimulated cells and localises to the cytoplasm 
13 
 
(Klint, Hellman et al. 2004). In contrast, TAF15 phosphorylation on Tyr residues by v-Src causes 




The amino-terminus of EWS present in the fusion protein EWS-FLI1 is post-translationally 
modified by O-linked-β-N-acetylglucosaminylation affecting the same sites as Ser/Thr 
phosphorylation. This is supposed to render the two modifications mutually exclusive thereby 
modulating transactivation activity of EWS-FLI1 (Bachmaier, Aryee et al. 2009). 
 
1.1.2.3 Methylation 
Post-translational methylation of arginine residues is frequently found in RNA-binding proteins 
and is thought to affect protein-RNA and protein-protein interactions as well as protein stability 
and subcellular localization (Liu and Dreyfuss 1995). The structure of arginine allows for mono- 
or di-methylation, which can be symmetric or asymmetric. Type I protein arginine 
methyltransferases (PRMTs) mono- and asymmetrically methylate arginine residues, whereas 
mono- and symmetric methylation is administered by Type II PRMTs. FET proteins have been 
found to be substrates of PRMT1, a type I PRMT. Accordingly, FUS/TLS contains over 20 
asymmetrically methylated arginine residues within its RGG motifs (Rappsilber, Friesen et al. 
2003). Likewise, the RGG sites of EWS are extensively methylated, with infrequent mono-
methylation events among the predominantly asymmetrically dimethylated arginines 
(Belyanskaya, Gehrig et al. 2001; Pahlich, Bschir et al. 2005). This methylation was found to 
impact cellular localization and transcriptional activity of EWS through nuclear exclusion and 
exposure on the cell surface (Belyanskaya, Delattre et al. 2003; Araya, Hiraga et al. 2005). 
Similarly, the modifications of arginine residues in TAF15 were shown to affect its gene 
regulatory functions and cellular localization in vivo. Arginine methylation resulted in nuclear 
localization of TAF15, whereas the inhibition of this modification resulted in cytoplasmic 
concentration of TAF15 into dense foci identified as stress granules (Jobert, Argentini et al. 
2009). 
A brain-specific variant of EWS resulting from alternative splicing (Melot, Dauphinot et al. 2001) 
was also found to be methylated by a Type I PRMT, PRMT8, which is located to the cell surface 




1.1.3 Putative and Validated Functions 
The FET family proteins are considered to be multifunctional RNA-binding proteins which 
integrate gene expression into a tightly regulated cellular machinery rather than a plain 
succession of transcription, RNA processing, transport and translation (Keene and Lager 2005; 
Law, Cann et al. 2006). According to their stability, almost ubiquituous expression and type of 
promoter FET proteins were at first regarded as housekeeping genes (Plougastel, Zucman et al. 
1993; Aman, Panagopoulos et al. 1996; Morohoshi, Ootsuka et al. 1998). Meticulous analysis of 
expression patterns and subcellular localization, however, points to partially overlapping but 
unique, cell type specific functions of EWS, FUS/TLS and TAF15 (Andersson, Stahlberg et al. 
2008). 
The FET proteins are implicated in various cellular processes such as transcription (Immanuel, 
Zinszner et al. 1995; Bertolotti, Lutz et al. 1996; Hoffmann and Roeder 1996; Bertolotti, Melot et 
al. 1998; Zhang, Paley et al. 1998; Tan and Manley 2010), splicing (Deloulme, Prichard et al. 
1997; Knoop and Baker 2000; Chansky, Hu et al. 2001; Lerga, Hallier et al. 2001), micro-RNA 
(miRNA) processing (Gregory, Yan et al. 2004), RNA transport (Calvio, Neubauer et al. 1995; 
Zinszner, Sok et al. 1997), signalling (Andersson, Stahlberg et al. 2008) and maintenance of 
genomic integrity (Hicks, Singh et al. 2000; Spahn, Petermann et al. 2002; Li, Watford et al. 2007; 
Wang, Arai et al. 2008). Nevertheless, their particular functions remain poorly characterized. 
 
1.1.3.1 Nucleic acid binding specificities of FET proteins 
FET proteins have been shown to bind RNA as well as single-stranded and even double-stranded 
DNA (Crozat, Aman et al. 1993; Ohno, Ouchida et al. 1994; Prasad, Ouchida et al. 1994; 
Bertolotti, Lutz et al. 1996; Hackl and Luhrmann 1996; Zinszner, Sok et al. 1997; Perrotti, Bonatti 
et al. 1998), a capability found in a comparably small number of proteins (Cassiday and Maher 
2002). Additionally, EWS has been found to specifically target G-quadruplex DNA and RNA in 
vitro via the arginine residue of its carboxy-terminal RGG-motif (Takahama, Kino et al. 2011). G-
quadruplexes are DNA secondary structures formed by single-stranded, G-rich human telomeric 
DNA (Sen and Gilbert 1988; Dai, Carver et al. 2008). Intriguingly, FUS/TLS was also found to bind 
to telomeres (Dejardin and Kingston 2009). The sequence-specificity of FET protein binding to 
RNA and DNA has been studied by several research groups so far. Shortly after its identification, 
EWS was found to bind to poly G and poly U sequences via its carboxy-terminal RGG domain 
(Ohno, Ouchida et al. 1994). Successive studies established similar binding affinities for FUS/TLS. 
An in vitro systematic evolution of ligands by exponential enrichment (SELEX) experiment (Tuerk 
and Gold 1990) implied FUS/TLS to bind GGUG-containing RNAs through its RBD and RGG motifs 
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(Lerga, Hallier et al. 2001). Furthermore, FUS/TLS was recently found to bind small, single-
stranded low-copy-number RNAs tethered to the promoter of cyclin D1 (Wang, Arai et al. 2008).  
As mentioned above, FET proteins also bind single-stranded and double-stranded DNA. FUS/TLS 
was shown to be involved in D-loop formation, a process essential for DNA repair and 
homologous recombination (Baechtold, Kuroda et al. 1999; Bertrand, Akhmedov et al. 1999). 
DNA-binding of FET proteins is most likely mediated by the C2/C2 zinc finger, a domain frequently 
found in transcription factors. There are, however, reports of RBDs mediating DNA-binding in a 
sequence-specific manner (Ding, Hayashi et al. 1999). On the other hand, the FET zinc finger 
domain resembles those present in ZIS, which is a protein involved in splicing (Ladomery and 
Dellaire 2002). In addition, the results of Iko et al. strongly suggest the zinc finger domain of 
FUS/TLS to bind to RNA, whereas the RBD exhibited no apparent interaction (Iko, Kodama et al. 
2004). The RGG-boxes present in FET proteins are thought to increase binding affinity rather 
than specificity and may serve as sites of post-translational modifications that regulate RNA 
binding (Burd and Dreyfuss 1994). 
Correspondingly, Cabeza/SARFH was found to localize to sites of active RNA polymerase II 
transcription and could be shown to bind RNA in vitro involving the RBD (Immanuel, Zinszner et 
al. 1995; Stolow and Haynes 1995). 
So far, little is known about the DNA/RNA binding specificities of TAF15 and still further 
investigations are required to learn more about the specificity, affinity and function of the 
nucleic acid-binding domains of the remaining FET proteins. Promising results concerning global 
RNA-targets for human FET proteins were recently obtained from large-scale PAR-CLIP 
experiments, which detected preferential binding of FET proteins near splice acceptor sites 
(Hoell, Larsson et al. 2011). 
 
1.1.3.2 FET proteins and RNA Transcription 
The initial connection between FET proteins and gene expression originated from the findings 
that the amino-terminal SYGQ-rich domains of EWS and FUS/TLS function as potent 
transcriptional activation domains in their respective oncogenic fusions (May, Lessnick et al. 
1993; Prasad, Ouchida et al. 1994). Subsequently, the same region of TAF15 was shown to 
possess transactivation potential (Bertolotti, Bell et al. 1999). A plethora of scientific findings 




1.1.3.2.1 Direct regulation of transcription by FET proteins 
Transcription factor (TF) IID contains the TATA binding protein (TBP), various TBP associated 
factors (TAFs) in stoichiometric or sub-stoichiometric ratios, and non-TBP associated co-
activators. The resulting variations in TFIID composition are thought to affect promoter choice, 
recruitment of processing factors and transcription (Brou, Chaudhary et al. 1993). Each of the 
FET proteins was found to co-purify with functionally distinct fractions of the TFIID complex in a 
sub-stoichiometric ratio strongly suggesting a common role in transcription initiation and 
elongation (Bertolotti, Lutz et al. 1996; Bertolotti, Melot et al. 1998). In fact, EWS and TAF15 
have been found to contact the same TAFs in a direct protein-protein interaction assay but could 
not be co-purified, suggesting the presence of EWS and TAF15 in the same TFIID complex to be 
mutually exclusive (Bertolotti, Melot et al. 1998). 
Furthermore, FUS/TLS, EWS and TAF15 have been shown to associate with subunits of RNA 
polymerase (RNAP) II itself thereby possibly affecting RNAPII mediated transcription (Bertolotti, 
Lutz et al. 1996; Bertolotti, Melot et al. 1998). Consistently, Cabeza/SARFH was also found to 
associate with transcribed chromatin in Drosophila (Immanuel, Zinszner et al. 1995) which 
further supports an evolutionarily conserved involvement of FET proteins in RNA transcription. 
hsRPB7 is the seventh largest subunit of RNAPII and together with hsRPB4 forms a sub-complex 
that may function in promoter recognition, similar to the stress-specific prokaryotic σ factor 
(Petermann, Mossier et al. 1998). TAF15 was shown to bind directly to hsRPB3, hsRPB5 and 
hsRPB7, whereas germline EWS was only able to interact with hsRPB3 (Bertolotti, Melot et al. 
1998). Carboxy-terminally truncated EWS, however, was shown to interact with hsRPB4 and 






Figure 4. Model for EWS activation domain (EAD)-mediated transactivation. Only select components 
of the transcription complex are depicted for simplicity reasons. The EAD binds the promoter via the 
DNA binding domain of the fusion protein and directly contacts RPB7. Recruitment of RPB4/7 into 
RNAPII is required for efficient transactivation. EAD – EWS-activation domain; DBD – DNA-binding 
domain; RPB4/7 – RNA polymerase subunit B4/7; Pol II – RNA polymerase II; TBP – TATA-binding 
protein; TATA – TATA-box. (modified from Zhou and Lee, 2001)  
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Nevertheless, it is not clear whether the respective FET fusion proteins of EWS and TAF15 are 
also able to interact with RNAPII. Although the involved amino-terminal region of EWS is also 
present in EWS-FLI1, Bertolotti et al. could find no proof for an interaction between the fusion 
protein and RNAPII (Bertolotti, Melot et al. 1998). In contrast, the results of Petermann et al. 
suggest not only an interaction between EWS-FLI1 and RNAPII but they claim that 
overexpression of recombinant RBP7 causes increased EWS-FLI1 mediated transactivation 
(Petermann, Mossier et al. 1998). Indeed, the function of the amino-terminal domain of 
germline FET-proteins is still poorly characterized. Experiments involving artificial fusions of FET 
proteins and DNA-binding domains revealed that the FET RBD strongly and specifically inhibited 
transactivation of the AD in cis (Li and Lee 2000; Rossow and Janknecht 2001). Subsequently, it 
was demonstrated that multiple RGG-motifs within the RBD are not only sufficient to repress the 
AD in cis but can also achieve this effect in trans upon dimer formation (Alex and Lee 2005). 
 
1.1.3.2.2 Indirect regulation of transcription by FET proteins 
Besides directly associating to general transcription factors and RNAPII, FET proteins might 
possibly affect transcription regulation by addressing interacting activators or repressors. 
FUS/TLS has been identified to be one of a few proteins that bind to nuclear hormone receptors 
without diminishing their ability to bind DNA thus influencing transcription activation of various 
steroid and thyroid hormone and retinoid receptors (Powers, Mathur et al. 1998). The 
interaction between the transcription factor Spi-1/PU.1 and FUS/TLS in vivo reduces the DNA-
binding and transactivating ability of Spi-1/PU.1 (Hallier, Lerga et al. 1998). Additionally, FUS/TLS 
has been reported to act as coactivator in NFκB-mediated transcription (Uranishi, Tetsuka et al. 
2001). EWS, on the other hand, was found to have a positive effect on CBP/p300-dependent 
transcription activation via the transcription factors HNF-4 (Araya, Hirota et al. 2003) and OCT-4 
(Lee, Rhee et al. 2005). HNF-4 is enriched in the liver and belongs to the nuclear receptor 
superfamily while OCT-4 is known to be involved in maintaining an undifferentiated totipotent 
state in germ cells and embryonic stem cells. The interaction between EWS and p300 is blocked 
by serine-threonine kinase receptor-associated protein (STRAP) which inhibits the activating 
effect on HNF-4 and OCT-4 (Anumanthan, Halder et al. 2006). In addition, EWS inhibits BRN3A-
dependent transcription, which is thought to promote development of the nervous system 
(Thomas and Latchman 2002). 
Hume et al. demonstrated that EWS binds directly to the promoter of the CSF-1 receptor (CSF1R) 
gene and the consensus binding sites for the myeloid zinc finger protein 1 (Mzf1) in vivo and in 
vitro whereas for FUS/TLS the same behaviour could only be observed in vitro. These findings 
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suggest proteins of the FET family to be involved in transcriptional start site recognition of TATA-
less mammalian promoters (Hume, Sasmono et al. 2008). 
As mentioned earlier, Takahama et al. established EWS as capable of binding G-quadruplexes 
which are known to be telomeric structures (Takahama, Kino et al. 2011) but have also been 
suggested to be formed by G-rich sequences near transcription start sites (Sen and Gilbert 1988; 
Verma, Halder et al. 2008). This implicates once more a role for FET proteins in transcription 
control. Indeed, the Akt/PKB substrate PRAS40 was recently identified as EWS target gene 
(Huang, Nakai et al. 2012). The PRAS40 3'UTR is G-rich and could potentially form a G-
quadruplex structure. EWS was found to associate directly with PRAS40 3'UTR thus negatively 
regulating PRAS40 expression which resulted in reduced proliferation and metastatic potential 
of Ewing Sarcoma cell lines (Huang, Nakai et al. 2012). 
Dominant point mutations in two RNA-binding proteins, TDP-43 and FUS/TLS, were found to 
cause a subset of familial amyotrophic lateral sklerosis (ALS), an incurable neurodegenerative 
disease affecting motoneurons (Kim, Shanware et al. 2010). Single nucleotide changes within the 
highly conserved last 13 amino acids of FUS/TLS resulted in increased cytoplasmic localization of 
aggregated FUS/TLS (Kwiatkowski, Bosco et al. 2009; Vance, Rogelj et al. 2009). The exact role of 
FUS/TLS in familial ALS remains to be elucidated, however, the convergent phenotypes resulting 
from mutations in FUS/TLS and TDP-43 point to their being elements of the same pathway. 
Indeed, FUS/TLS and TDP-43 were found to form a functional complex which co-regulates 
expression of histone deacetylase (HDAC) 6 mRNA (Kim, Shanware et al. 2010). 
Interestingly, FUS/TLS represses transcription by RNAPIII via controlling the access of TBP and 
the RNAPIII machinery to target genes (Tan and Manley 2010). RNAPIII transcribes small 
untranslated RNAs, such as 5S rRNA and U6 snRNA. Thus, FUS/TLS now lists with a number of 
cancer-related factors like Rb and p53 that are capable of controlling multiple polymerases 
which suggests a more complex role for FET proteins in context of the transcriptome (Tan and 
Manley 2010). 
 
1.1.3.3 FET Proteins and Splicing 
FET proteins have been suggested to function in splicing almost as long as they have been 
known. FUS/TLS was identified by nano electrospray mass spectrometry as hnRNP P2 of the H 
complex that assembles specifically on pre-mRNAs in vitro (Calvio, Neubauer et al. 1995). 
Accordingly, FUS/TLS was subsequently found to specifically bind to the 3' splice site during the 
second step of pre-mRNA splicing (Wu and Green 1997). FUS/TLS and EWS were shown to 
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participate in the same complex with the splicing factor polypyrimidine-tract-binding-protein 
associated factor (PSF) (Deloulme, Prichard et al. 1997). Correspondingly, FUS/TLS was 
subsequently identified as component of a large protein complex containing 
hyperphosphorylated RNAPII, U1 snRNP, p54nrb, PSF and various transcription elongation factors 
located at the 5' splice site (Kameoka, Duque et al. 2004) and – as already mentioned above - 
specifically binds to the GGUG motif commonly found in 5' splice sites (Lerga, Hallier et al. 2001). 
The presence of FET proteins in the spliceosome was confirmed involving large-scale purification 
of intact functional spliceosomes as well as mass spectrometric tools (Rappsilber, Ryder et al. 
2002; Zhou, Licklider et al. 2002).  
FET proteins were found to associate with a variety of SR proteins and other splicing factors. As 
mentioned earlier, all FET proteins associate with the splicing factor/transcriptional repressor 
SF1/ZMF1 (Zhang, Paley et al. 1998). FUS/TLS was shown to interact with the SR proteins TLS-
associated serine-arginine protein (TASR) and SC35 via its carboxy-terminal RGG motifs (Yang, 
Embree et al. 1998; Lerga, Hallier et al. 2001). It also associates with SRp75, SRm160 and PTB 
(Meissner, Lopato et al. 2003) as well as the hnRNPs A1 and C1/C2 (Zinszner, Albalat et al. 1994). 
Moreover, EWS and EWS-FLI1 were proven to associate with U1C which – being one of three 
human U1 small nuclear ribonucleoprotein-specific proteins – interacts with various other 
splicing factors and plays an important role in spliceosome formation (Knoop and Baker 2000). 
The carboxy-terminal domains of EWS and FUS/TLS were found to interact with the splicing 
activator YB-1 thereby recruiting YB-1 to hyperphosphorylated RNAPII (Chansky, Hu et al. 2001). 
Dutertre and co-workers reported the interaction between EWS and YB-1 to be inhibited after 
exposure to various inducers of genotoxic stress, which resulted in the cotranscriptional skipping 
of several exons of the MDM2 gene coding for the main p53 ubiquitin ligase (Dutertre, Sanchez 
et al. 2010). TAF15 was currently found to participate in interactions with a subset of the 
spliceosomal U1 snRNP complex (Leichter, Marko et al. 2011) suggesting that the TAF15-U1 
snRNP complex serves a similar function to the one proposed for TIA-1-U1 snRNP, which is 
thought to participate in the selection of a specific subset of pre-mRNAs for splicing (Forch, Puig 
et al. 2002). 
The most recent results on this topic strongly support all of the above listed evidence for a role 
of FET proteins in pre-mRNA splicing. EWS depletion was reported to result in alternative splicing 
changes of genes involved in DNA damage repair and genotoxic stress signalling, including ABL1, 
CHEK2 and MAP4K2. Accordingly, depletion of EWS caused a reduction of cell viability and 
proliferation upon UV irradiation, an effect that was reversed upon restoration of c-ABL 
expression (Paronetto, Minana et al. 2011). 
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The idea of pre-mRNA processing and transcription as an integrated pathway rather than two 
separate processes has been established over the previous years (Bentley 1999; Hirose and 
Manley 2000; de Almeida and Carmo-Fonseca 2008; Moore and Proudfoot 2009) and it is very 
likely that they are linked by multifunctional proteins such as the FET family of proteins (Tan and 
Manley 2009). In the recent years considerable evidence was collected supporting the role of 
FET proteins as mediators between the individual processes of gene expression, which has 
already been discussed above to some extent. The amino-terminal domain of EWS was found to 
interact with BARD1 (Spahn, Petermann et al. 2002). BARD1 is known to be associated with 
BRCA1 and has been shown to interact with the polyadenylation factor CstF-50 (Kleiman and 
Manley 1999). The BARD1/BRCA1/CstF-50 complex mediates a transient inhibition of 
polyadenylation after DNA damage (Kleiman and Manley 2001; Kim, Li et al. 2006). Furthermore, 
FUS/TLS has been found to interact with CIP29, a protein associated with the DEAD box RNA 
helicase DDX39 (Sugiura, Sakurai et al. 2007). DEAD-box proteins, like DDX39, have been 
functionally implicated in diverse processes including RNA transcription, RNA splicing, mRNA 
transport, translation initiation and cell cycle regulation (Rocak and Linder 2004; Rosner and 
Rinkevich 2007). Interestingly, EWS-FLI1 but not EWS was found in association with RNA helicase 
A (Toretsky, Erkizan et al. 2006). FUS/TLS and Cabeza/SARFH have been found to localize to sites 
of active transcription and were suggested to function in transcriptional regulation together with 
other RNPs (Calvio, Neubauer et al. 1995; Immanuel, Zinszner et al. 1995). In addition, all human 
FET proteins have been found to be associated with distinct subpopulations of TFIID complexes 
(Bertolotti, Lutz et al. 1996; Bertolotti, Melot et al. 1998). Consequently, Kameoka et al. found 
FUS/TLS to be part of large RNAPII-snRNP complexes involving various transcription and splicing 
factors such as PSF, U1 snRNP and p54nrb (Kameoka, Duque et al. 2004). 
 
1.1.3.4 FET proteins and RNA transport 
FET proteins are localised mostly to the nucleus corresponding to their proposed functions in 
gene regulation and transcription (Hackl and Luhrmann 1996; Alliegro and Alliegro 1997; 
Zinszner, Immanuel et al. 1997; Andersson, Stahlberg et al. 2008). Hackl and Lührmann reported 
a subnuclear localization of TAF15 to speckles (Hackl and Luhrmann 1996) while Andersson et al. 
observed a smooth nuclear localization of FET family proteins in cultured human cells with 
FUS/TLS and TAF15 but not EWS showing also a diffuse distribution in the cytoplasm (Andersson, 
Stahlberg et al. 2008). Zinszner et al., on the other hand, reported a change in nucleic 
distribution of FUS/TLS from a diffuse pattern to an accumulation into dense nuclease-resistant 
aggregates upon inhibition of RNAPII mediated transcription (Zinszner, Immanuel et al. 1997). In 
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fact, there is evidence that FET proteins shuttle between the nucleus and the cytoplasm and are 
involved in RNA transport. FUS/TLS was identified as being identical to hnRNP P2 (Calvio, 
Neubauer et al. 1995) which corresponds to the observation that FUS/TLS shuttles between the 
nucleus and the cytoplasm in complexes containing mRNA and various hnRNPs (Zinszner, Sok et 
al. 1997). Besides, FUS/TLS was found to participate in mRNA sorting to dendritic spines upon 
mGluR5 activation in mouse hippocampal pyramidal neurons (Fujii, Okabe et al. 2005; Fujii and 
Takumi 2005). Thus, FET proteins are implicated in the distribution of cytoplasmic factors for 
local translation. 
Belyanskaya and co-workers found EWS shuttling from the nucleus to the cell surface depending 
on its methylation status (Belyanskaya, Gehrig et al. 2001; Belyanskaya, Delattre et al. 2003). 
However, the relevance of this finding remains to be ascertained. 
 
1.1.3.5 FET proteins and maintenance of genomic integrity  
A close interdependence of transcription and genome stability has been observed in S. 
cerevisiae, where proteins that function at the interface of RNA metabolism and transcription 
affect genomic stability by regulating transcription-associated recombination (Luna, Jimeno et al. 
2005). 
Similarly, FUS/TLS was found to promote homologous DNA pairing and D-loop formation which 
are key processes in homologous recombination (Baechtold, Kuroda et al. 1999; Bertrand, 
Akhmedov et al. 1999). Subsequently, EWS was observed to interact with BRCA1-associated 
BARD1 (Spahn, Petermann et al. 2002). In addition, FET proteins together with the splicing factor 
PSF were shown to bind specifically to homologous DNA in vitro (Guipaud, Guillonneau et al. 
2006) which hints to a role for FET proteins in the DNA repair pathway. This agrees with the 
above mentioned finding of Gardiner et al. that FUS/TLS but not FUS-CHOP is phosphorylated 
after induction of DNA damage (Gardiner, Toth et al. 2008).  Correspondingly, the knockout of 
FUS/TLS in mice resulted in a pleiotropic effect on B-lymphocyte development, B-cell activation 
and genomic stability - resulting from defects in chromosomal pairing and enhanced radiation 
sensitivity – which is reminiscent of disruptions of c-Abl and Atm (Tybulewicz, Crawford et al. 
1991; Hardin, Boast et al. 1995; Barlow, Hirotsune et al. 1996; Xu and Baltimore 1996; Hicks, 
Singh et al. 2000; Kuroda, Sok et al. 2000). Both, c-ABL and ATM kinase are activated upon DNA 
damage and target FUS/TLS which likely explains why FUS/TLS-deficient cells display high levels 
of genomic instability (Perrotti, Bonatti et al. 1998; Gardiner, Toth et al. 2008). Additionally, 
FUS/TLS is thought to link DNA repair and cell cycle by transcriptionally repressing cyclin D1 via 
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recruiting a non-coding RNA that inhibits CBP/p300 at the cyclin D1 promoter (Wang, Arai et al. 
2008). 
Accordingly, EWS knockout in mice resulted in a similar phenotype including defects in pre-B 
lymphocyte development, reduced meiotic recombination, defective gamete maturation and 
sensitivity to ionizing radiation (Li, Watford et al. 2007). However, EWS and FUS/TLS are not 
functionally redundant since molecular details of EWS and FUS/TLS deficiencies are different. 
EWS-null spermatocytes displayed reduced number of meiotic crossovers and high levels of 
unsynapsed XY sex chromosomes while FUS/TLS-knockout resulted in defective autosomal 
bivalent formation (Kuroda, Sok et al. 2000; Li, Watford et al. 2007). Decreased meiotic 
crossovers could likely be an indirect consequence of XY asynapsis which strongly suggests a 
direct role for EWS in meiotic recombination (Li, Watford et al. 2007). Furthermore, EWS 
deficiency resulted in infertility of both sexes while loss of FUS/TLS only caused male sterility 
(Kuroda, Sok et al. 2000; Li, Watford et al. 2007). In zebrafish, morpholino-induced knockdown 
of EWS orthologs caused developmental defects, apoptosis of pre-neural cells and embryonic 
lethality which was confirmed by results from HeLa cells, where siEWS also induced mitotic 
defects and apoptosis (Azuma, Embree et al. 2007). Together, these results implicate specific, 
non-redundant and evolutionarily conserved roles for FET family proteins in DNA repair and 
surveillance of genomic integrity. 
 
1.1.3.6 FET proteins and miRNA processing 
EWS has recently been suggested to be involved in the micro RNA (miRNA) mediated gene 
regulation since it was found in a complex together with the nuclear RNase III DROSHA, RNA 
helicases, doublestrand RNA-binding proteins and hnRNPs (Gregory, Yan et al. 2004). DROSHA 
cleaves primary (pri-)miRNA transcripts in the nucleus generating pre-miRNAs of about 60-70nt 
length thereby initiating miRNA processing and transport to the cytoplasm (Lee, Ahn et al. 2003). 
Subsequently, pre-miRNAs are processed by another RNase III enzyme, Dicer, to generate the 
final ~22nt miRNAs which guide RISC-mediated mRNA degradation (Bernstein, Caudy et al. 2001; 
Grishok, Pasquinelli et al. 2001; Hutvagner, McLachlan et al. 2001; Bartel 2004). Furthermore, 
FET proteins have been found to colocalize to stress granules with components of the miRNA 
processing machinery (Leung, Calabrese et al. 2006; Andersson, Stahlberg et al. 2008) which 
could hint to functions in the regulation of post-transcriptional gene expression during normal 
and stress-induced situations. Moreover, deregulation of miRNA-mediated gene-regulation has 
been implicated to play a major role in cancer development as miRNAs are key-regulators of 
many biological processes such as development, cell proliferation, differentiation and apoptosis 
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(Lagos-Quintana, Rauhut et al. 2003; Thomson, Newman et al. 2006; Sassen, Miska et al. 2008; 
Riedmann and Schwentner 2010). However, the functional significance of the association 
between EWS and DROSHA for the regulation of miRNAs remains to be determined. 
Furthermore, FET proteins could also be involved in the generation of miRNAs via their 
involvement in the splicing process. Most miRNA genes are located in noncoding regions of the 
genome but about 25% of human miRNAs have been identified in introns of protein-coding 
genes (Bartel 2004; Ying and Lin 2004). Thus, one might speculate that FET proteins not only link 
transcription to splicing but also splicing to miRNA generation from gene introns (Kovar 2011). 
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1.2 Ewing Tumors 
Sarcomas are a class of mostly sporadic, relatively rare but aggressive malignancies with a high 
tendency towards dissemination and relapse that constitute less than 10% of human 
malignancies but about 15% of paediatric cancers (Riggi, Cironi et al. 2007). The cellular origin of 
these tumors remains largely unknown but there is evidence that they develop from 
mesenchymal progenitor cells as a result of genetic alterations (Riggi, Cironi et al. 2007). Soft 
tissue sarcomas were found to affect more adults whereas bone sarcomas are more common in 
children and adolescents (Riggi, Cironi et al. 2007; Osuna and de Alava 2009). The identification 
of characteristic genetic aberrations for the specific sarcoma subtypes has advanced the 
scientific and clinical understanding of these tumors (Bennicelli and Barr 2002). The finding that 
sarcomas can rather be defined by their molecular pathology than by their organ or tissue of 
origin has enabled the development of more efficient targeted therapies (Helman and Meltzer 
2003). Ewing sarcoma (ES) result from genomic translocations fusing the 5' part of a FET family 
protein to the 3' portion of an ETS-family transcription factor, thereby giving rise to an aberrant 
transcription factor (Law, Cann et al. 2006). 
 
1.2.1 Pathogenesis, Characteristics and Tissue of Origin 
Ewing sarcoma was first described by the American pathologist James Ewing (figure 5) in 1921 as 
a diffuse endothelioma of the bone (Ewing 1921). ES are the second most common bone 
malignancy in children and young adults and comprise a class of poorly differentiated tumors 
including Ewing sarcomas and primitive peripheral neuroectodermal tumors (PPNETs) (Riggi, 
Cironi et al. 2007). ES affects slightly more males than 
females (male: female ratio = 1.2:1) and is more frequent 
in Caucasians than Asians, African-Americans or Africans 
with a peak incidence around 15 years of age (Bernstein, 
Kovar et al. 2006; Jawad, Cheung et al. 2009). Typical 
sites of primary ES are the pelvic bones, the long bones 
of the lower extremities and the bones of the chest wall 
with primary metastases in lung, bone and/or bone 
marrow detectable in about 25% of patients (Bernstein, 
Kovar et al. 2006) (figure 6). The initial symptoms include 
intermittent strain-like pain and a palpable mass which 
often lead to misdiagnosis since the onset of symptoms 
was often reported to coincide with minor trauma 
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occurring at approximately the same time (Widhe and Widhe 2000). Thus, plain radiograph is 
usually performed as initial measure, however, the most precise definition of the local extent of 
disease can be achieved by magnetic resonance imaging (figure 7) while the definitive diagnostic 





Characteristically, ES consists of small round cells with a high nuclear to cytoplasm ratio that are 
arrayed in sheets (Bernstein, Kovar et al. 2006). Due to their similar cell morphology ES, 
neuroblastoma, alveolar rhabdomyosarcoma and lymphoblastic lymphoma are also referred to 
as small round blue cell tumors (Riggi, Cironi et al. 2007). Additionally, ES cells strongly express 
the cell surface marker p30/32MIC2 (CD99) and exhibit immunoreactivity for vimentin (Dierick, 
Roels et al. 1993; Weidner and Tjoe 1994). However, the histologic and immunophenotypic 
features of ES resemble to varying extent other paediatric small round blue cell tumors. Thus, 
detection of characteristic translocations and other genetic aberrations involving fluorescence in 
situ hybridisation (FISH) and/or RT-PCR are often necessary for definitive diagnosis. 








The karyotype of ES is relatively 
simple harbouring only few numerical 
and structural aberrations (Bernstein, 
Kovar et al. 2006). All ESs are 
characterized by reciprocal 
translocations resulting in the 
expression of one of several fusion 
proteins, the most prominent being 
EWS-FLI1 (Turc-Carel, Aurias et al. 
1988; Delattre, Zucman et al. 1992) followed by EWS-ERG and the much less frequent EWS-ETV-
1,EWS-E1AF, EWS-FEV and FUS-ERG (Sorensen, Lessnick et al. 1994; Kovar 1998; Law, Cann et al. 
2006; Riggi, Cironi et al. 2007; Mackintosh, Madoz-Gurpide et al. 2010)(for more detail see also 
section 1.2.2). Additional numerical and structural aberrations with prognostic relevance have 
been observed in ES, the most frequent being gain of chromosomes 8 and 12, loss of 9p and 16q 
and the non-reciprocal translocation t(1;16)(q12;q11.2) causing gain of 1q (Mugneret, Lizard et 
al. 1988; Armengol, Tarkkanen et al. 1997; Hattinger, Rumpler et al. 1999; Lopez-Guerrero, Pellin 
et al. 2001; Hattinger, Potschger et al. 2002). 
The introduction of EWS-ETS fusion proteins into diverse cellular systems evoked variant 
responses, reaching from growth arrest over induction of apoptosis to dedifferentiation 
(Thompson, Teitell et al. 1999; Deneen and Denny 2001; Lessnick, Dacwag et al. 2002; Zwerner, 
Guimbellot et al. 2003). Accordingly, the cellular context is a major determinant since 
development of ES requires cells with a certain degree of plasticity and permissiveness for EWS-
FLI1-induced transformation. Nevertheless, the actual tissue of origin for ES is still unclear. Bone 
marrow human mesenchymal stem cells (MSCs) are considered a probable cellular source since 
most ESs occur in bone and soft tissue. In fact, the gene expression profile of ES cells after 
knockdown of EWS-FLI1 was most similar to that of mesenchymal progenitor cells (Tirode, Laud-
Duval et al. 2007; Kauer, Ban et al. 2009). This corresponds well with the finding that expression 
of EWS-FLI1 in human MSCs induced a gene expression profile resembling that of ES (Riggi, Suva  
Figure 7. Ewing tumor in the 
femoral diaphysis. (a) 
anteroposterior radiograph. (b) 
Coronal short tau inversion recovery 
MRI. (O'Donnell 2003) 
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et al. 2008). Kauer et al. obtained an EWS-FLI1-specific gene expression pattern from the 
comparison of EWS-FLI1 knockdown in five ES cell lines and 59 primary ESs using mesenchymal 
progenitor cells as a reference tissue (Kauer, Ban et al. 2009). Previously, Hancock et al. acquired 
an expression signature based on a meta-analysis of EWS-FLI1 dependent gene expression data 
from different models obtained from various expression profiling platforms (Hancock and 
Lessnick 2008). However, the resulting profiles of the two studies share only little significant 
overlap although the overall overlap between the gene lists affected by EWS-FLI1 is strong. This 
is most likely due to the use of different reference tissues (Kovar 2010). 
Moreover, EWS-ETS fusion proteins were shown to block osteogenic and adipogenic 
differentiation which is consistent with the observed undifferentiated phenotype of Ewing 
tumor cells (Torchia, Jaishankar et al. 2003). The generation of ES-like tumors from murine MSCs 
expressing EWS-FLI1 has already been achieved in mice (Castillero-Trejo, Eliazer et al. 2005; 
Riggi, Cironi et al. 2005). Mouse bone marrow-derived mesenchymal progenitor cells (MPCs) 
were shown to maintain expression of retrovirally introduced EWS-FLI1 and formed tumors 
upon injection into severe combined immunodeficient (SCID) mice (Riggi, Cironi et al. 2005). 
These tumors were found to display hallmarks of ES, such as round cell phenotype, expression of 
CD99 and NSE, growth dependence to IGF-R1 and altered expression of several known EWS-FLI1 
target genes (Riggi, Cironi et al. 2005). Suva and colleagues identified a subpopulation of CD133+ 
tumor cells with the capability to initiate and sustain tumor growth through the course of serial 
transplantations in immunodeficient mice displaying plasticity similar to MSCs (Suva, Riggi et al. 
2009). Very recently, a transgenic model of ES was established in zebrafish (Leacock, Basse et al. 
2012). The expression of human EWS-FLI1 in Danio rerio resulted in tumors with ES-like histology 
and allowed for the identification of an EWS-FLI1 gene expression signature in zebrafish which 
disclosed substantial conservation of EWS-FLI1 targets between fish and human (Leacock, Basse 
et al. 2012). Taken together, these findings point to a mesenchymal cellular origin of ES although 




 DNA-binding domain Cancer Translocation Frequency 
 CHOP Myxoid liposarcoma t(12;16)(q13;p11)  
 ERG Acute myeloid leukemia t(16;21)(p11;q22)  
FUS/TLS ATF-1 Angiomatoid fibrous histiocytoma t(12;16)(q13;p11)  
 CREB312/BBF2H7 Low-grade fibromyxoid sarcoma t(7;16)(q33;p11)  
 ERG Ewing tumors t(16;21)(p11;q22) <1% 
 FLI1 Ewing tumors t(11;22)(q24;q12 85% 
 ERG Ewing tumors t(21;22)(q22;q12) 10% 
 ETV1 Ewing tumors t(7;22)(q22;q12) <1% 
 ETV4/E1AF Ewing tumors t(17;22)(q12;q12) <1% 
 FEV Ewing tumors t(2;22)(q33;q12) <1% 
 CHOP Myxoid liposarcoma t(12;22)(q13;q12)  
EWSR1 ATF-1 Malignant melanoma of soft parts/ soft tissue 
clear cell sarcoma 
t(12;22)(q13;q12)  
 WT1 Desmoplastic small round cell tumor t(11;22)(q13;q12)  
 ZSG Small round cell sarcoma t(1;22)(p36.1;q12)  
 POU5F1 (OCT3/4) Undifferentiated bone sarcoma t(6;22)(p21;q12)  
 CHN/TEC Extraskeletal myxoid chondrosarcoma t(9;22)(q22;q12)  
 CIZ/NMP4 Acute leukemia t(12;22)(p13;q12)  
TAF15 CHN/TEC Extraskeletal myxoid chondrosarcoma t(9;17)(q22;q11.2)  





1.2.2 The fusion proteins of Ewing sarcoma 
The predominant genetic feature of 85% of ESs is a chromosomal translocation, 
t(11;22)(q24;q12), which fuses two genes, EWSR1 and Friend leukemia integration 1 (FLI1) (Turc-
Carel, Aurias et al. 1988; Delattre, Zucman et al. 1992). Of the remaining cases approximately 10-
15% are characterised by the fusion of EWS and ERG and 1-5% express EWS-ETV-1, EWS-E1AF, 
EWS-FEV or FUS-ERG (Sorensen, Lessnick et al. 1994; Kovar 1998; Law, Cann et al. 2006; Riggi, 
Cironi et al. 2007; Mackintosh, Madoz-Gurpide et al. 2010) (table 1). EWS belongs to the FET 
family of RNA-binding proteins and has already been described in detail (see section 1.1). The 
FLI1 gene locus was first identified as the integration site of Friend murine leukemia virus (Ben-
David, Giddens et al. 1991). FLI1 is a member of the ETS family of transcription factors which 
activate their target genes by binding to purine-rich GGA(A/T) DNA sequences through their 
conserved ETS domains in cooperation with other transcription factors and co-factors (Wasylyk, 
Hahn et al. 1993; Oikawa and Yamada 2003). The amino-terminus of FLI1 consists of one pointed 
domain that mediates protein-protein interactions and one FLI1 specific transactivation domain 
with a helix-loop-helix structure (Rao, Ohno et al. 1993). The carboxy-terminal domain includes 
the ETS DNA binding domain and a second, weaker transactivation domain (Rao, Ohno et al. 
1993)(see also figure 8). The amino- and carboxy-terminal transactivation domains achieve their 
maximal transactivation potential through intramolecular interaction (Rao, Ohno et al. 1993). 
Depending on the cellular context and the respective promoter FLI1 can act as a transcriptional 
Table 1. Fusion genes of FUS/TLS, EWS and TAF15 in human cancer. Relative frequencies of 
gene fusions in ES as indicated. (modified from Law and Cann, 2006)  
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repressor or activator, however, more genes containing the consensus FLI1 binding site are up-
regulated (Rao, Ohno et al. 1993). In contrast, subsequent studies of the EWS-FLI1 fusion protein 
revealed a predominant negative regulatory function of the FLI1 carboxy-terminal 
transactivation domain (Arvand, Welford et al. 2001). FLI1 is expressed in hematopoietic cell 
lineages and vascular endothelial cells (Oikawa and Yamada 2003). Additionally, it is involved in 
erythroid, myelomonocytic and NK cell development (Masuya, Moussa et al. 2005) and acts as a 
key regulator of megakaryocytic differentiation (Jackers, Szalai et al. 2004). The target genes of 
FLI1 include oncogenes, tumor suppressor genes and genes with functions in apoptosis, 
differentiation, angiogenesis and invasion (Sharrocks 2001; Oikawa and Yamada 2003; Asano, 








The predominant and best characterized genetic fusion of a FET protein and an ETS transcription 
factor in ES is EWS-FLI1 (Delattre, Zucman et al. 1992; Zucman, Delattre et al. 1992). The fusion 
gene is under control of the EWS promoter on der(22), the reciprocal translocation product, 
FLI1-EWS, is not expressed and is even occasionally lost from ES cells (Bernstein, Kovar et al. 
2006). Several different in frame fusion genes have been described resulting from variant 
breakpoint positions, the most prevalent being type I between EWS exon 7 and FLI1 exon 6 and 
type II between EWS exon 7 and FLI1 exon 5 (Delattre, Zucman et al. 1992; Zucman, Melot et al. 
Figure 8. Structure of the EWS-FLI1 fusion protein. The amino-terminal domain of EWS is 
fused to the carboxy-terminal  domain of FLI1. Due to variable break point positions in both 
genes the resulting  protein has a variable fusion region and length. FLI1 protein structure: PD 
- amino-terminal pointed domain; AD - FLI1 specific activation domain; ets-domain -  carboxy-
terminal ETS-domain. For detailed depiction of EWS protein structure see figure 3. (figure 
modified from Bachmaier 2007)  
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1993; Zoubek, Dockhorn-Dworniczak et al. 1996; de Alava, Kawai et al. 1998) (figure 8). It has 
been observed that the transcription factor partners seem to be linked to the specific tumor 
type while the EWS or FUS parts are functionally interchangeable and show no such association 
(Zinszner, Albalat et al. 1994; Aman, Panagopoulos et al. 1996; Li, Watford et al. 2007). The 
transformation capability of EWS-ETS fusions varies in different cellular backgrounds: NIH3T3 
and bone marrow-derived mesenchymal progenitor cells were transformed by EWS-FLI1 in 
contrast to human or rat primary fibroblasts, mouse embryonic stem cells and embryonic 
fibroblasts [(Thompson, Teitell et al. 1999; Torchia, Jaishankar et al. 2003; Zwerner, Guimbellot 
et al. 2003; Riggi, Cironi et al. 2005) for review see also (Kovar 2005)]. Additionally, EWS-ERG was 
shown to induce neoplasia from lineage-committed haematopoietic cells (Codrington, Pannell et 
al. 2005). 
 
1.2.2.1 Transcriptional functions of ES fusion proteins 
EWS-FLI1 is a potent transcriptional modulator with unique properties which corresponds to its 
predominantly nuclear localization (Yang, Chansky et al. 2000). Although EWS-FLI1 was found to 
be able to dimerize and also weakly interact with germline EWS it binds to DNA as monomer 
(Spahn, Siligan et al. 2003) and in collaboration with additional factors, such as Fos-Jun (AP-1) or 
RHA (Kim, Denny et al. 2006; Toretsky, Erkizan et al. 2006). The generation of gene expression 
profiles from ES samples and ES cell lines enabled the definition of EWS-FLI1-specific signatures 
using mesenchymal progenitor cells as reference (Tirode, Laud-Duval et al. 2007; Kauer, Ban et 
al. 2009). Kauer and colleagues found the majority of EWS-FLI1 up-regulated genes to relate to 
cell cycle and cell proliferation whereas genes with functions in cell differentiation and 
morphogenesis were generally down-regulated which reflects the characteristic undifferentiated 
phenotype of ES (Kauer, Ban et al. 2009). This corresponds well with the finding that silencing of 
EWS-FLI1 restored plasticity of ES cells towards adipogenic, neuronal and osteogenic 
differentiation (Tirode, Laud-Duval et al. 2007) whereas ectopic expression of EWS-FLI1 in 
mesenchymal stem cells blocked differentiation potential and induced the initial steps towards 
ES development [(Riggi, Cironi et al. 2005; Riggi, Suva  et al. 2008) (for a summary of validated 
direct targets of EWS-FLI1 see also table 2)]. Furthermore, promoter regions of EWS-FLI1 






Consequences of target suppression References 
Id2 Not known (Fukuma, Okita et al. 2003) 
GLI1 Reduced anchorage independent growth 
(Beauchamp, Bulut et al. 2009; Joo, 
Christensen et al. 2009) 
VEGF Decreased osteolysis 
(Fuchs, Inwards et al. 2004; Guan, Zhou 
et al. 2009) 
STYXL1 Not known (Siligan, Ban et al. 2005) 
PLD2 Inhibition of PDGF BB signalling (Kikuchi, Murakami et al. 2007) 
PTPL1 Reduced growth, increased chemosensitivity (Abaan, Levenson et al. 2005) 
CAV1 
Reduced anchorage independent growth, reduced 
tumorigenicity 
(Tirado, Mateo-Lozano et al. 2006) 
GSTM4 
Abrogation of oncogenic transformation, increased 
chemosensitivity 
(Luo, Gangwal et al. 2009) 
NR0B1 Abrogation of oncogenic transformation 
(Kinsey, Smith et al. 2006; Mendiola, 
Carrillo et al. 2006; Kinsey, Smith et al. 
2009) 
EZH2 
Reduced anchorage independent growth, reduced 
tumorigenicity 
(Richter, Plehm et al. 2009) 
AURKA, AURKB Not known (Wakahara, Ohno et al. 2008) 
Tenascin C Not known (Watanabe, Nishimori et al. 2003) 
   
EWS-FLI1 repressed 
genes 
Consequences of target restoration References 
TGFBR2 Loss of tumorigenicity (Hahm, Cho et al. 1999) 
CDKN1A Inhibition of cell growth (Nakatani, Tanaka et al. 2003) 
IGFBP3 Inhibition of cell growth and motility 
(Prieur, Tirode et al. 2004; Benini, Zuntini 
et al. 2006) 
FOXO1 Not known (Yang, Hu et al. 2010) 
DKK1 Decreased tumorigenicity 
(Miyagawa, Okita et al. 2009; Navarro, 




variety of DNA sequence motifs was found in repressed genes. This can be interpreted as 
suggestive for a less complex transcriptory regulation upstream of EWS-FLI1 up-regulated genes 
and points to a more direct role of EWS-FLI1 in gene activation than in gene repression (Kauer, 
Ban et al. 2009). Indeed, EWS-FLI1 has been previously identified as an activating transcription 
factor in vitro (May, Lessnick et al. 1993; Bailly, Bosselut et al. 1994). However, the mechanism 
of target selection of oncogenic ETS fusion proteins is poorly understood. EWS-FLI1 was found to 
bind specifically to GGAA microsatellite sequences that are significantly enriched in EWS-FLI1 
regulated genes such as NR0B1 and GSTM4 thus suggesting a mechanism to direct fusion protein 
activity (Gangwal, Sankar et al. 2008; Luo, Gangwal et al. 2009). Correspondingly, ChIP-Seq 
revealed GGAA microsatellites and bona fide ETS binding site containing regions as EWS-FLI1 
binding regions in ES cells (Guillon, Tirode et al. 2009). Interestingly, it was suggested that the 
lack of GGAA microsatellites in murine genes might be the reason for persisting problems in the 
establishment of genetically engineered mouse models of ES, since the expression of EWS-FLI1 
would not up-regulate critical genes required for oncogenic transformation, e.g. murine Nr0b1 
Table 2. Validated direct EWS-FLI1 target genes (modified from Kovar, 2011) 
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and Cav1 (Kinsey, Smith et al. 2006; Tirado, Mateo-Lozano et al. 2006; Gangwal, Sankar et al. 
2008). 
 
1.2.2.2 Post-transcriptional functions of ES fusion proteins 
Besides its relatively well studied function as aberrant transcriptional regulator, EWS-FLI1 has 
been implicated in post-transcriptional processing, too. Functional dissection studies of EWS-
FLI1 in NIH3T3 transformation assays first suggested that the minimal transforming and the 
minimal transcriptional activation domains can be separated from each other (Lessnick, Braun et 
al. 1995). Subsequently, the fusion protein was shown to retain residual transforming activity 
after destruction of the DNA-binding domain by point mutations or deletions (Jaishankar, Zhang 
et al. 1999; Welford, Hebert et al. 2001). In addition, EWS-FLI1 was found to achieve an 
antiapoptotic effect through interference with CBP-dependent transcriptional activity of RXR 
which appears to be independent of DNA binding (Ramakrishnan, Fujimura et al. 2004). 
The amino-terminal domains of the ES fusion proteins have been demonstrated to interact with 
the same RNA processing factors as their germline counterparts thus potentially interfering with 
the respective functions (Yang, Embree et al. 1998; Zhang, Paley et al. 1998; Knoop and Baker 
2000; Yang, Chansky et al. 2000; Chansky, Hu et al. 2001; Knoop and Baker 2001). EWS-FLI1 and 
FUS/TLS-ERG inhibit YB-1 mediated splicing as they fail to recruit the splicing factor to RNAPII 
(Chansky, Hu et al. 2001). Accordingly, EWS and FUS/TLS were shown to recruit SR splicing 
factors to hyperphosphorylated RNAPII thereby coupling RNA transcription to splicing. EWS-FLI1 
as well as FUS/TLS fusions interferes with this function as they retain the ability to associate with 
RNAPII but fail to recruit SR proteins (Yang, Embree et al. 1998; Yang, Chansky et al. 2000). The 
splicing factor U1C, which is important in early stages of spliceosome formation, associates with 
EWS as well as with EWS-FLI1 and was shown to repress EWS-FLI1-mediated transactivation. 
This illustrates the connecting function of EWS/EWS-FLI1 between transcriptional and post-
transcriptional processes (Knoop and Baker 2000). Furthermore, EWS-FLI1, but not EWS, was 
shown to interfere with hnRNP A1-dependent 5' splice site selection in vivo which was found to 
coincide with the transforming activity of the fusion protein (Knoop and Baker 2001). Quite 
recently, EWS-FLI1 was found to influence splicing of the protooncogene cyclin D1 (CCND1) 
favouring the oncogenic splice isoform D1b over D1a by decreasing the elongation rate of RNAPII 
(Sanchez, Bittencourt et al. 2008). This indicates that the fusion protein’s role in post-
transcriptional processing may not be regarded as transcription independent. 
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As already mentioned before, the effects of FET fusion proteins depends on the cellular 
background. Expression of EWS-FLI1 induced p53-dependent cell cycle arrest in primary human 
fibroblasts (Lessnick, Dacwag et al. 2002) and most other cell types were not found permissive to 
EWS-FLI1 expression (for review see (Kovar 2005)). This can be explained by the triggering of the 
p53 checkpoint through the oncogenic stress imposed by fusion transcript expression (Ban, 
Bennani-Baiti et al. 2008). ES circumvent this by modulating p53 activity either directly (Li, 
Tanaka et al. 2010) or via interference with the tumor suppressive NOTCH signalling pathway 
(Ban, Bennani-Baiti et al. 2008). Additionally, there is evidence for EWS-FLI1-mediated 
interference with other principal tumor suppressor pathways since knockdown of EWS-FLI1 
resulted in hypophosphorylation and functional activation of pRb-1 thus evoking a senescence-
like phenotype in ES cells (Hu, Zielinska-Kwiatkowska et al. 2008). 
 
1.2.3 Prognostic factors and novel therapeutic approaches 
ES is the second most frequent primary bone malignancy affecting mostly children and 
adolescents during their second decade of life. Since its first description in 1921 (Ewing 1921) 
efforts have been taken to elucidate the mechanisms of this disease in order to fuel prognostic 
and therapeutic progress and thus improve the outcome for the patients. 
 
1.2.3.1 Prognosis 
To date, a number of factors with prognostic value have been identified for ES. Besides 
responsiveness to chemotherapy (Jurgens, Exner et al. 1988), tumor volume and location 
(Gehan, Nesbit et al. 1981; Glaubiger, Makuch et al. 1981; Jurgens, Exner et al. 1988; Koscielniak, 
Jurgens et al. 1992; Abudu, Davies et al. 1999) the structure of the fusion transcript has been 
considered a major determinant of prognosis (de Alava, Kawai et al. 1998; Lin, Brody et al. 1999). 
At least 12 alternative in-frame fusions of EWS and FLI1 resulting from different genomic 
breakpoints have been clinically documented (Zucman, Melot et al. 1993). The two most 
frequently observed fusion types between EWS exon 7 and FLI1 exon 6 (type I) and EWS exon 7 
and FLI1 exon 5 (type II) represent about 60% and 25%, respectively, of EWS-FLI1 fusions 
(Zucman, Melot et al. 1993; Zoubek, Dockhorn-Dworniczak et al. 1996; de Alava, Kawai et al. 
1998). EWS-FLI1 type I was suggested to be transactivationally less active resulting in a less 
aggressive tumor phenotype (Lin, Brody et al. 1999). However, this could not be confirmed by 
the prospective evaluation of fusion transcript structure in 565 patients which abrogated the 
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status of the fusion gene as independent prognostic marker due to the lack of statistical 
significance (Le Deley, Delattre et al. 2010). 
Furthermore, the presence of metastasis has proven to be a most unfavourable prognostic 
feature (Cangir, Vietti et al. 1990; Paulussen, Ahrens et al. 1998; Cotterill, Ahrens et al. 2000). 
About 25% of patients are diagnosed initially with metastatic disease (Bernstein, Kovar et al. 
2006). The worst chances of survival are associated with bone or bone marrow metastases 
(≤20%) as opposed to pulmonary metastases, which have a slightly better outcome (about 30% 
survival)(Paulussen, Ahrens et al. 1998). In comparison, localised ES results in relapse-free 
survival of about 70% (Potratz, Dirksen et al. 2012). However, despite improved therapeutic 
measures, about 30% of patients experience relapse, either locally, distantly or combined which 
is tantamount to dismal prognosis (Bernstein, Kovar et al. 2006). The risk for relapse is 
significantly higher for patients with primary metastatic disease (Cotterill, Ahrens et al. 2000) 
and the chance for long-term survival after relapse is reduced to 20-25% with timing and type of 
recurrence being crucial prognostic determinants (Rodriguez-Galindo, Billups et al. 2002). The 
worst prognosis is associated with early (after less than two years) or combined local and distal 
recurrence (Shankar, Pinkerton et al. 1999; Rodriguez-Galindo, Billups et al. 2002). Recently, 
gene expression signatures were defined that discriminate between patients with fatal 
etiopathology or more favourable prognosis allowing for the identification of patients with ES 
nonresponsive to current treatments (Scotlandi, Remondini et al. 2009). 
Moreover, a number of molecular prognostic factors have been defined so far. The before 
mentioned gain of 1q was shown to have predictive value adverse overall and event-free survival 
(Hattinger, Potschger et al. 2002). Loss of 16q was found to be closely associated with 
disseminated disease (Hattinger, Potschger et al. 2002). However, the most predominant 
chromosomal aberrations present in 50-60% of ESs, gain of chromosome 8 and chromosome 12, 
have never manifested prognostic value in clinical studies (Hattinger, Rumpler et al. 1999). The 
transcription factor p53 is one of the most prominent tumor suppressors disrupted in various 
malignancies (Sherr and McCormick 2002). Still, p53 mutations are relatively rare in ES and can 
be found in about 10% of cases (Huang, Illei et al. 2005). Nevertheless, alterations in p53 specify 
a subset of ES with markedly poor clinical outcome (de Alava, Antonescu et al. 2000) which is 
also the case for homozygous deletions of the CDKN2A locus (p16INK4/p14ARF)(Tsuchiya, Sekine et 
al. 2000) or a combination of the two aberrations (Huang, Illei et al. 2005). Additionally, 20% 
overall survival at 2 and 5 years for patients with overexpression of p53 was opposed by 85% 2-
year survival and 71% 5-year survival of patients with normal p53 status (Abudu, Mangham et al. 
1999). The relative rarity of p53 aberrations in ES suggests that they are not essential for primary 
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oncogenesis but may - as second hit-alterations - define a tumor subset with particularly 
aggressive behaviour, poor chemoresponse and thus dismal prognosis (Abudu, Mangham et al. 
1999). Low expression levels of p27KIP1, as can be found in about 76% of ESs, were shown to be 
associated with poor event-free survival (Matsunobu, Tanaka et al. 2004). Forced expression of 
p27KIP1 reduced phosphorylated pRb as well as cell growth and promoted apoptosis in ES cells 
(Matsunobu, Tanaka et al. 2004). Malfunction of the transcription factor c-Myc is often 
implicated in cancer development and in fact, expression of c-Myc is strongly induced by EWS-
FLI1 which leads to an activation of CDK4 and Id2 transcription (Dauphinot, De Oliveira et al. 
2001). Furthermore, the G1 cyclin-CDK complex inhibitor p57KIP2 (Dauphinot, De Oliveira et al. 
2001) and the tumor suppressor p21WAF1 (Maitra, Roberts et al. 2001) were found to be 
downregulated in ESs, the prognostic significance of this is however unclear. 
 
1.2.3.2 Treatment 
Current treatment of ES involves primary chemotherapy which is followed by local therapy, 
comprising either surgery or radiotherapy or both (Dunst, Sauer et al. 1991), and adjuvant 
chemotherapy (Bernstein, Kovar et al. 2006). Planning of the optimal local therapy requires an 
interdisciplinary team of experienced experts since local treatment should be individually 
adapted depending on the site and size of the tumor (Bernstein, Kovar et al. 2006). For patients 
with recurrent disease there is no established treatment procedure. Usually, a combination of 
multiagent chemotherapy and local control measures is administered (Jurgens, Exner et al. 1988; 
Paulussen, Ahrens et al. 1998; Paulussen, Ahrens et al. 1998; Rodriguez-Galindo, Billups et al. 
2002). However, Chemotherapy options depend on the patient's prior treatment and are limited 
by potential impairment of organ function (Bernstein, Kovar et al. 2006). 
Alternative therapeutic strategies that counteract the neoplastic process have been proposed 
and are being tested in preclinical models [for review see (Potratz, Jurgens et al. 2012)]. The 
novel approaches can be subdivided aiming at one of six possible mechanisms of carcinogenesis 
(Olsen, Tarantolo et al. 2002): First, disruption of chimeric transcription factor activity; second, 
prevention of post-translational modifications stimulating cellular growth; third, recovering 
function of tumor suppressors; fourth, inhibition of angiogenesis; fifth, induction of apoptotic 
pathways and sixth, introduction of toxic gene products. 
Since the EWS-ETS fusion genes are unique to ES cells they pose potentially ideal therapeutic 
targets. Several approaches to disrupt EWS-FLI1 function have been reported including antisense 
methods (Ouchida, Ohno et al. 1995; Kovar, Aryee et al. 1996; Tanaka, Iwakuma et al. 1997; 
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Toretsky, Connell et al. 1997; Matsumoto, Tanaka et al. 2001; Asami, Chin et al. 2008), short 
hairpin RNA (shRNA) (Nozawa, Ohno et al. 2005; Garcia-Aragoncillo, Carrillo et al. 2008; Herrero-
Martin, Osuna et al. 2009) and small interfering RNA (siRNA) (Chansky, Barahmand-Pour et al. 
2004; Prieur, Tirode et al. 2004; Takigami, Ohno et al. 2011) which lead to increased apoptosis, 
reduced invasiveness and growth inhibition in vitro and in xenografted tumors. Two challenges 
remain to be solved regarding these approaches: First, efficient delivery of the reagents to the 
tumor site (Lambert, Bertrand et al. 2000; Hu-Lieskovan, Heidel et al. 2005; Toub, Bertrand et al. 
2006; Elhamess, Bertrand et al. 2009) and second, possible long term side effects (Grimm, 
Streetz et al. 2006). 
Furthermore, a number of different approaches to disrupt EWS-FLI1 function have been 
suggested. For instance, small pharmacological compounds have been found to either interfere 
with the expression of EWS-FLI1 downstream targets (Mateo-Lozano, Gokhale et al. 2006; 
Stegmaier, Wong et al. 2007; Grohar, Woldemichael et al. 2011) or block one of its protein-
protein interactions (Erkizan, Kong et al. 2009) thereby reducing xenograft growth [for review 
see also (Metallo 2010)]. For instance, high-throughput screens identified mithramycin and 
cytosine arabinoside (ARA-C) as inhibitors of ES growth either by modulating EWS-FLI1 activity or 
fusion protein abundance, respectively (Stegmaier, Wong et al. 2007; Grohar, Woldemichael et 
al. 2011). Rapamycin was found to significantly delay tumor development in vivo (Mateo-Lozano, 
Gokhale et al. 2006) and the S-enantiomer of YK-4-279 was shown to specifically inhibit the 
interaction of EWS-FLI1 with RHA thus inducing apoptosis in ES cells (Erkizan, Kong et al. 2009; 
Barber-Rotenberg, Selvanathan et al. 2012). 
Another example is the inhibition of the above mentioned O-linked-β-N-acetylglucosaminylation 
of EWS-FLI1 which was shown to interfere with the transactivation of the downstream target Id2 
(Bachmaier, Aryee et al. 2009). With further investigations to better understand the 
physiological mechanisms behind this process it constitutes a probable basis for novel therapies 
against ES. 
Promising results have been achieved with the MDM2 antagonist Nutlin-3a (Pishas, Al-Ejeh et al. 
2011; Sonnemann, Palani et al. 2011). Since p53 mutations are relatively rare in ES the activation 
of wild-type p53 function could be a promising therapeutic strategy. The E3 ubiquitin ligase 
MDM2 negatively regulates the activity and protein levels of the tumor suppressor p53. Nutlin-
3a blocks the interaction of MDM2 and p53 thus stabilizing the tumor suppressor protein which 
induces p53-dependent apoptosis. 
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Additionally, blockage of the autocrine IGF-1/IGF-1R loop by antagonistic antibodies has also 
been shown to inhibit ES cell growth in vivo (Scotlandi, Benini et al. 1998; Toretsky and Gorlick 
2010). However, Garofalo and colleagues found that insulin receptor (IR)-A causes an intrinsic 
and adaptive resistance to anti-IGF-1R drugs suggesting that tumors with a low IGF-1R: IR-A ratio 
might not respond well to IGF-1R-directed therapies (Garofalo, Manara et al. 2011). 
Another therapeutic alternative is the blockage of tumor vessel formation. Vascular endothelial 
growth factors (VEGFs) are key regulators of angiogenesis and vasculogenesis and have been 
found to be overexpressed in various tumors which seems to be correlated with adverse 
prognosis (Ferrara 2004). Blocking of VEGF receptor 2 with the antibody DC101 disrupted 
VEGF165 signalling thus reducing tumor vessel density and tumor growth (Zhou, Bolontrade et 
al. 2007). Furthermore, EWS-FLI1 and VEGF165 were shown to increase receptor activator NF-κB 
ligand (RANKL) promoter activity thereby contributing to the osteolytic process induced by ES 
cells. Thus, ES-associated osteolysis could possibly be reduced by DC101 treatment (Guan, Zhou 
et al. 2009). 
Deregulation of miRNA expression, too, has been implicated in cancer development (Calin and 
Croce 2006; Thomson, Newman et al. 2006; Ma and Weinberg 2008; Sassen, Miska et al. 2008; 
Garzon, Calin et al. 2009). In fact, EWS-FLI1 and miR-145 were only recently identified to form a 
feedback loop where the fusion protein represses expression of the miRNA to which it is itself a 
target (Riggi, Suva et al. 2010; Ban, Jug et al. 2011). Consequently, targeting miRNAs which affect 
fusion protein activity might provide another avenue to ES therapy. 
A critical determinant for solid tumor growth is adaptation to hypoxia, which modulates many 
aspects of tumor biology and response to therapy (Wilson and Hay 2011). In ES, hypoxia was 
found to transiently enhance EWS-FLI1 expression (Aryee, Niedan et al. 2010) thus offering new 
possibilities for innovative therapeutic methods. 
Finally, Ordonez et al. have also suggested immunotherapeutic approaches involving both, 
specific antibodies and/or cellular therapy mediated by natural killer (NK) cells, as an optional 
future treatment for ES patients (Ordonez, Osuna et al. 2009). ES cells have proven to possess 
some unique immunologic features, such as complete or partial absence of class I and class II 
HLA which is mainly associated with advanced tumor stages (Berghuis, de Hooge et al. 2009). 
Moreover, although ES cells are specifically resistant to the cytolytic death-receptor pathway, 
they retain sensitivity to the perforin/granzyme pathway (de Hooge, Berghuis et al. 2007). 
However, further studies are required to gain insight into the connection between ES 






2. Hypothesis and Aims of the Study 
 
Generally, only one allele of EWS (or FUS/TLS) is rearranged with an ETS transcription factor in 
ES resulting in co-expression of the fusion protein and germline EWS. So far, there is only one 
known case of ES where the expression of endogenous EWS was lost from the cancer cells 
(Kovar, Jug et al. 2001). Furthermore, EWS is co-expressed and has been found to interact with 
its oncogenic derivative (Spahn, Siligan et al. 2003). Based on this finding in addition to the 
current knowledge of FET protein function (as summarized in section 1.1) the following 
hypothesis was established: 
EWS plays a role in mRNA transcription and processing and EWS-FLI1 interferes with this normal 
EWS function in a competitive or dominant negative manner. This interference is thought to 
contribute to the oncogenic activity of EWS-FLI1. 
To get a better understanding of the functional interaction or competition between EWS and 
EWS-FLI1 and to define its impact on mRNA transcription and processing in the ET background, 
we aimed at the characterisation of a EWS-specific transcriptomic signature. To this end, two 
independent model systems were established from two different ES cell lines: the before 
mentioned unique ET cell line lacking endogenous EWS was studied upon stable restoration and 
re-knockdown of EWS expression (EWS-restoration model or EWS-RM), and an ET cell line with 
stable EWS knockdown was analyzed upon inducible RNAi-mediated EWS-FLI1 suppression 
(EWS-knockdown model or EWS-KDM). These systems provided the means to study the 
influence of modulated EWS expression on genome wide transcript expression and exon 
composition. The EWS-RM was the main focus of the study, while the EWS-KDM was designed to 
serve validation purposes. Affymetrix HuEx-1.0stv2 exon array analysis of both models yielded a 
pangenomic picture of alternatively/aberrantly spliced/transcribed RNAs. Validation of 
microarray data concerning the influence of EWS on exon skipping was achieved by RT-qPCR. 
Differentially expressed genes depending on the presence of EWS were examined by 5’ RACE 
PCR to exclude the possibility of EWS dependent differential transcription start site selection as a 










3.1 Experimental system and cellular models: EWS-restoration model and EWS-
knockdown model 
To explore the influence of EWS on the ES 
transcriptome and the EWS-FLI1 signature an 
experimental strategy was developed tailored for 
the investigation of a possible effect of EWS on 
genome wide transcript expression and exon 
composition (figure 9). This strategy was based on 
two different ES cell lines, STA-ET-7.2 and A673, 
which were transformed in order to enable for 
the modulation of EWS and EWS-FLI1 expression. 
The resulting cellular model systems were termed 
EWS-reconstitution (EWS-RM) and EWS-
knockdown model (EWS-KDM), respectively (figure 
10.A and 10.B). Overall gene expression and exon 
composition were studied on Affymetrix Hu-Ex1.0 












The predominant cellular model of this study, the EWS-RM, was based on a unique ES cell line, 
STA-ET-7.2, that was first described by Kovar and co-workers (Kovar, Jug et al. 2001). In this cell 
line, the rearranged chromosome has been duplicated while the intact chromosome 22 was lost. 
Figure 9. Experimental system. 
Miniature traffic lights indicate 
modulations of EWS and EWS-FLI1 
expression. 
Figure 10. Cellular models. (A) EWS-
restoration model (EWS-RM) established in 
the STA-ET-7.2 ES cell line; lack of 
endogenous EWS expression was 
compensated by reconstitution of stable EWS 
expression; re-knockdown of EWS and 
knockdown of EWS-FLI1 was achieved by 
transient transfection of shRNA-expression 
vectors. (B) EWS-knockdown model (EWS-
KDM) based on the A673-shEF cell line; clones 
with disrupted EWS expression were obtained 
from stable transfections with shRNA-
expression vectors; knockdown of EWS-FLI1 

















Figure 11. EWS-restoration model. (A) Immunoblot analysis of four stable clones of STA-ET-7.2 cells 
with restored EWS expression (R37s, R7s, R33r and R34r) compared to a polyclonal culture of STA-ET-
7.2 cells transfected with the empty vector (pCMV Script) as a control (ctrlB and ctrlC). Approximately 
physiological protein levels of EWS were detected. (B) Hierarchial clustering of the six samples derived 
from the STA-ET 7.2 reconstitution system shows high within-group correlation between clones (+EWS) 
and control samples (-EWS). 
Figure 12. Re-knockdown of EWS from the EWS restoration model. (A) Immunoblot analysis of protein 
levels in clone R7s upon knockdown of EWS and/or EWS-FLI1 as indicated. Silencing efficiency of 
shEWSex11 was extremely high with low off-target effects on EWS-FLI1 protein levels. Silencing of EWS-
FLI1 generally caused a reduction of EWS protein levels, which was however less pronounced in other 
experiments. (B) Semi-quantitative PCR analysis of clone R37s including three validated EWS-FLI1 target 
genes after knockdown of EWS and/or EWS-FLI1 as indicated. E2F1 and VEGF are EWS-FLI1-activated, 
TGFβR2 is an EWS-FLI1-repressed gene. EWS and EWS-FLI1 RNA levels are significantly reduced upon 
introduction of the indicated shRNA-constructs. TGFβR2 and VEGF exhibit expression patterns 
corresponding to the respective EWS-FLI1 expression status. E2F1, however, seems to be reduced upon 




Thus, only the oncogenic fusion protein, EWS-FLI1, is expressed while endogenous expression of 
EWS is abolished. Reconstitution of EWS expression was achieved by transfection and selection 
of stable clones carrying the pCMV-Script-EWSα vector. Four clones (R7s, R37s, R33r and R34r) 
with approximately physiological levels of EWS expression were selected for further analysis 
(figure 11.A). Polyclonal cultures of STA-ET-7.2 cells stably transfected with the empty pCMV 
Script vector served as negative controls for this model (ctrlB and ctrlC). The hierarchial 
clustering shown in figure 11.B depicts the high within-group correlation between the four 
selected clones and the two control samples. 
As an internal control, shEWSex11, a shRNA targeting the 5’region of EWS, was designed to 
enable for re-knockdown of EWS. Additionally, two already established shRNAs targeting EWS-
FLI1, shEFsi22 and shEFsi4 (Kovar, Ban et al. 2003), were used to modulate fusion gene 
expression within this system. Knockdown of EWS and EWS-FLI1 was confirmed by Immunoblot 
analysis (figure 12.A) and semi-quantitative RT-PCR of validated EWS-FLI1 target genes (figure 
12.B). Knockdown efficiency on the protein level was monitored by Immunoblot analysis for all 
examined samples. A slight reduction of EWS protein levels upon transfection with shRNA 
targeting EWS-FLI1 could be observed in all experiments and was interpreted to result from 
stress induced changes in protein synthesis due to oncogene deprivation. However, the 
comparably low level of EWS protein upon silencing of EWS-FLI1 observed in clone R7s (figure 
12.A) was singular to the displayed experiment. Semi-quantitative RT-PCR was used to verify 
knockdown efficiency on RNA level for EWS and EWS-FLI1 directly, and downstream of EWS-FLI1 
by additionally testing for three validated targets of the fusion gene – E2F1, VEGF (both 
activated by EWS-FLI1) and TGFβR2 (repressed by EWS-FLI1). A significant reduction of EWS 
and/or EWS-FLI1 RNA levels was detected upon transfection with the corresponding shRNA-
expressing vectors (figure 12.B). Two EWS-FLI1 downstream targets, VEGF and TGFβR2, 
exhibited the expected expression patterns. However, E2F1 mRNA levels seemed to be 
increased upon double-knockdown of EWS and EWS-FLI1, while silencing of EWS alone reduced 
the expression of E2F1, which was observed in all examined clones (figure 12.B) 
The second cellular model, the EWS-KDM, was designed as a validation system for the data 
obtained from the EWS-RM. It was established in the ES cell line A673-shEF containing a 
Doxicyclin-inducible shRNA targeting EWS-FLI1, that was originally obtained from the group of 
Javier Alonso, Unidad de Tumores Solidos Infantiles, Instituto de Salud Carlos III, Majahonda, 
Spain (Carrillo, Garcia-Aragoncillo et al. 2007). The original ES cell line, A673, co-expresses EWS 
and EWS-FLI1 in contrast to the STA-ET-7.2 cell line. From this cell line two stable clones (KD7s 
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and KD10s) with knockdown of EWS were obtained. Knockdown efficiency was again confirmed 
by Western blot analysis (figure 13). A673 cells stably expressing a shRNA targeting GFP were 
used as control for A673-shEF cells, and A673-shEF cells stably transfected with either empty 
pSUPER.retro.puro vector or a non-target shRNA were used as controls for the stable 








3.2 Phenotypic effects of EWS 
Expression of EWS-FLI1 is the main characteristic feature and indispensable driver of sustained 
ES cell growth (Kovar, Zoubek et al. 1994). RNAi-mediated suppression of EWS-FLI1 expression 
results in growth inhibition, reduced viability and loss of tumorigenicity of ES cells (Ouchida, 
Ohno et al. 1995; Kovar, Aryee et al. 1996; Toretsky, Connell et al. 1997; Kovar, Ban et al. 2003). 
After the finding that germline EWS is dispensable for ES growth (Kovar, Jug et al. 2001), we 
were interested in the physiological consequences of EWS expression in STA-ET-7.2 cells. For this 
purpose, proliferation assays and colony formation assays were performed to monitor the 
effects of EWS under adherent as well as anchorage independent conditions. 
 
  
Figure 13. EWS-knockdown 
model. Two stable clones 
with disrupted EWS 
expression (KD7s and 
KD10s) were analysed on 
Immunoblot upon 
Doxicyclin-induced 
knockdown of EWS-FLI1 as 
indicated. A673 cells stably 
expressing a shGFP and 
A673-shEF cells transfected 
with non target-shRNA and 
empty vector (pSUPER. 
retro.puro), respectively, 
served as controls. 
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3.2.1 Proliferation Assays 
To determine whether EWS affects the growth of ES cells we compared the growth rates of STA-
ET-7.2 cells transfected with empty pCMV Script vector as a control and three clones stably 
expressing EWS (R7s, R37s and R33r) for a period of 96 hours. No significant growth advantage 
could be detected for cells expressing EWS in adherent culture (figure 14) which recapitulates 







3.2.2 Colony Formation Assays 
Additionally, we tested whether EWS has an effect on anchorage-independent growth of ES 
cells. STA-ET-7.2 cells stably transfected with empty vector were compared to three stable 
clones with restored EWS expression (R7s, R37s and R33r). A statistically highly significant effect 
could be observed with EWS-expressing cells forming almost thrice as many colonies than the 
control (figure 15.A and B). This effect could be reversed upon re-knockdown of EWS. All three 
clones were transiently transfected with either non-target shRNA or shRNA targeting EWS. A 
significant reversal of the growth advantage conveyed by EWS was detected as can be seen 
exemplary for clone R37s (figure 15.C and D). 
Taken together, the results from the functional assays are consistent with the suggested unique, 
non-redundant functions of FET proteins as compared to the housekeeping role that was 
attributed to this protein family in earlier studies, since they seem to be involved in specific 
processes, such as conveyance of anchorage-independent growth, rather than in the general 
maintenance of cellular functions. 
Figure 14. EWS expression does 
not affect anchorage dependent 
growth of STA-ET-7.2 cells. Growth 
rates of 3 EWS-expressing STA-ET-
7.2 clones (R7s, R37s, R33r) were 
compared to control cells 
transfected with empty vector 
(pCMV Script) in 24 hour-intervals 
over a time span of four days. EWS 
conferred no detectable advantage 
for anchorage-dependent growth 
to STA-ET-7.2 cells. Cell numbers 
were counted using a Bürker-Türk 
chamber; standard deviations of 
three independent experiments, 














Figure 15. EWS expression affects anchorage independent growth in soft agar colony 
formation assays. (A) Restoration of EWS expression effected a significant increase of 
clonogenicity of STA-ET-7.2 cells as could also be observed in the microscope (B). Re-
knockdown of reconstituted EWS leads to a reversion of the observed effect (C) and (D). 
Colonies were counted 17-20 days after seeding. (A)(C) Standard deviations resulting 
from three independent experiments, each performed in triplicate; statistical relevance 
was assessed involving the unpaired t-test. (B)(D) pictures taken at 50x magnification. 
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3.3 Microarray analyses 
In order to acquire a global picture of the EWS- and EWS-FLI1-effect on transcriptional and post-
transcriptional regulation, microarray analysis was performed. All experiments involving samples 
obtained from both cellular model systems (see table 3 for a list of samples) were hybridized on 
Affymetrix Hu-Ex1.0 stv2 chips. Figure 16 depicts the basic layout of these microarrays: With 
approximately four probes per exon and 40 probes per gene on average, this microarray 
platform enables two complementary levels of analysis—gene expression as well as exon 
composition. Hence, using this microarray platform, the analysis can be focused either on whole 
transcripts or on single exons. These two analyses can be merged into a “splicing” analysis where 
exons that deviate in their expression from whole-transcript expression are detected thus 
allowing for the detection of different isoforms of specific genes. Additionally, the Affymetrix 
Hu-Ex1.0 stv2 microarrays provide the possibility to analyse expression levels of whole 
transcripts by summarizing multiple probes on different exons into an expression value of all 
transcripts from the same gene. The data analyses are described in detail in the materials and 
methods section 5.2.7. “Exon graphs” were chosen to visualize our data retrieved from 




Table 3. Microarray samples. RNA samples obtained from stable clones as well as transient 
transfections (italics) were subjected to microarray analysis on Hu-Ex1.0 stv2 chips. +DOX 
indicates Doxicyclin-induced knockdown of EWS-FLI1 in the A673-shEF ES cell line; nt shRNA – 
















Utilizing the Affymetrix Hu-Ex1.0 stv2 microarray platform the following analyses were 
performed: First, analysis of expression level changes of whole transcripts in dependence of EWS 
and/or EWS-FLI1. Second, analysis of EWS and/or EWS-FLI1-dependent differential exon 
composition. 
  
Figure 16. Scheme of microarray analysis. Approximately four exon-centric probes 
per exon constitute one probe set; one gene is defined by forty specific probes on 
average. PSR – probe selection region. Diagram by Affymetrix, Santa Clara, CA. 
Figure 17. Schematic representation of an exon graph. In the upper panel, a basic 
graph with four sections representing exons 1-4 of gene X can be seen. The red and 
blue line depict relative expression levels of these exons with or without expression 
of EWS, respectively. The resulting alternative transcripts are schematically 
represented in the lower part of the figure. 
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3.3.1 Analysis of whole transcript expression 
In total, we found 689 genes up- and 694 genes down-regulated upon restored EWS expression 
in STA-ET-7.2 cells with a fold change of at least 1.5 fold for a p-value cutoff of <0.3. Re-
knockdown of EWS from the EWS-RM effected negative expression changes in 320 genes and 
increased expression in 673 genes (see figure 18.A and B, columns 1-4,  for top ranking 
examples). The effect of restored EWS expression could be reversed in 32 of the EWS-activated 
and in 117 of the EWS-repressed genes. Hence, for approximately 150 genes the gene 
expression changes induced by reconstitution of EWS expression could be rescued by the 
silencing of ectopically expressed EWS in this model system. This confirms the EWS-specificity of 
the observed effects. The effect of EWS-FLI1 silencing on the selected genes from the EWS-RM 
did not show a clear tendency of activation or repression (figure 18.A and B, column 3). 
Nevertheless, certain genes, such as CAB39L, DDIT4, BAMBI, UCP2 and LGR5, exhibited EWS- and 
EWS-FLI1-dependent expression patterns matching one of two possible models of functional 
cooperation between EWS and EWS-FLI1 (see also figure 19 and the last paragraph of this 
section). 
Subsequently, we aimed for validation of these results by analysis of the EWS-KDM. However, 
the data overlap between the two cellular systems was very small. No significant effect of EWS 
in the EWS-KDM could be detected for genes selected from the EWS-RM (figure 18.A and B, 
columns 5-7; see also figure 21 and section 3.3.1.1). 
From the total transcript expression data two subsets of genes were defined which in their EWS 
and EWS-FLI1 dependent expression patterns matched with one of two alternative models of 
functional relationship between EWS and EWS-FLI1. Genes such as C3AR1 and LGR5 are 
repressed respectively induced by EWS while EWS-FLI1 influences their expression to the 
opposite effect. Thus, they conform to a “functional competition model” in which EWS and EWS-
FLI1 both directly influence the expression of target genes in opposite directions (figure 19.A). 
The expression patterns of genes like SULF1 and PLCXD1 on the other hand were found to 
correspond to a “functional interference model”, where EWS-FLI1 interferes with the gene 













Figure 18. Heat maps of EWS de-regulated genes. Genes displaying an effect of EWS on gene expression 
in the EWS-RM were selected (logFC > 1.5, adjusted p < 0.3). (A) EWS-repressed genes (B) EWS-activated 
genes. The selected genes show an opposite effect of EWS reconstitution and re-knockdown in STA-ET-7.2 
cells (columns 1 and 2). While the effect of EWS-FLI1 silencing on the expression levels of the selected 
genes showed no clear tendency (column 3), additional knockdown of EWS turned the effect in the same 
direction as single-knockdown of EWS from the EWS-RM (column 4). However, only some genes selected 
from the EWS-RM for their EWS-dependent changes in expression showed the same tendencies in the 





Figure 19. Functional relationship models of EWS and EWS-FLI1. (A) Functional competition model: 
EWS as well as EWS-FLI1 exert a direct effect on the target gene; top ranking examples for this model 
can be seen in the heat map on the left (adjusted p < 0.3). (B) Functional interference model: EWS-FLI1 
does not affect expression of the target gene directly but interferes with the EWS-effect. Since EWS-FLI1 
represses EWS function, effects on transcript expression can only be detected in case of EWS-FLI1 
knockdown in the presence of EWS, while EWS-knockdown does not produce an alteration regarding 
expression levels (adjusted p < 0.3). x-axis – EWS/EWS-FLI1 status; y-axis – relative expression levels; 
light blue bars – expression level is not changed upon alteration of the EWS/EWS-FLI1 status as 
























To ascertain the general relevance of our findings from the EWS-RM we aimed for validation 
involving the EWS-KDM based on the A673 ES cell line. The number of genes exhibiting 
significant changes in expression levels was comparable between knockdown of EWS from the 
EWS-KDM (1481 genes) and restoration of EWS in the EWS-RM (1383 genes). Surprisingly, the 
overlap between the two systems was relatively low (46 genes) and even decreased further 
when the re-knockdown of EWS in the EWS-RM was taken into account (10 genes: CAB39L, 
C3AR1, RALGPS2, ENPEP, DDIT4, BAMBI, PLXDC2, CLUL1, UCP2, LGR5) (figure 21). This result 
points to a strong inherent distinctness of the two cell lines which probably roots in their 
respective evolution with or without expression of EWS. 
Figure 21. Overlap of data obtained from EWS-RM and EWS-KDM regarding transcript levels. (A) EWS-
activated genes. Restoration of EWS expression in STA-ET-7.2 cells leads to elevated expression levels in 689 
genes. Silencing of EWS leads to a reversion of the effect in about 5% of genes (32 genes). Knockdown of 
EWS expression in A673-shEF cells decreases expression levels of 771 genes, however, only 2 genes overlap 
with the data obtained from the EWS-RM, LGR5 and UCP2 (see figure 18.A). Genome graph from the re-
knockdown of EWS in the EWS-RM for LGR5 can be seen on the right hand side. (B) EWS-repressed genes. 
117 genes inversely correspond to restored respective re-silenced EWS-expression in STA-ET-7.2 cells but 
only 8 of these can also be found in data obtained from the EWS-KDM. Genome graph for one of the genes, 
CAB39L, from the re-knockdown of EWS in the EWS-RM can be seen on the right hand side. Green lines – 
gene expression levels in the presence of EWS (+EWS); orange lines – gene expression levels in the absence 
of EWS (-EWS); red circles ≙ EWS-RM (EWS-restoration model/STA-ET-7.2 cell line); blue circles ≙ EWS-KDM 
(EWS-knockdown model/A673-shEF cell line); exon fold change > 2; adjusted p < 0.3. 
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3.3.1.2 Functional annotation of top-ranking genes 
Functional annotation of the top ranking EWS up- and down-regulated genes was performed by 
GSEA (gene set enrichment analysis) using the “pGSEA” package in the Bioconductor/R 
environment (Kim and Volsky 2005; Subramanian, Tamayo et al. 2005). Predominant among the 
EWS repressed genes in the EWS-RM were the functional terms “RNA processing”, “RNA 
splicing” and “cell cycle” (figure 20.A). “Cell signaling” including G-protein coupled, neuropeptide 
and chemokine receptor signaling was most prevalent among functions connected with EWS 
activated genes. Notably, the observed reversion of the effect exerted by restored EWS 
expression on gene expression levels after re-knockdown of EWS was even more pronounced on 
the functional level: the effects of absent EWS expression are highly consistent whether the 
original STA-ET-7.2 cell line or re-silenced EWS expression is compared to samples with restored 
EWS (figure 20.A, columns I and II). EWS-FLI1 knockdown was observed to have an opposite 
effect on the top-ranking EWS-regulated GO terms (figure 20.A, column III). Interestingly, 
double-knockdown of EWS and EWS-FLI1 in the EWS-RM resulted in down regulation of the 


















Figure 20. Gene set enrichment analysis (GSEA) identifies top enriched GO terms associated with EWS 
expression. (A) GSEA of the EWS-RM. Correlation of gene expression changes upon reconstituted/re-
silenced EWS expression confirms EWS-specificity of the observed effect (columns I and II). On a 
functional level, EWS-FLI1 silencing has an opposite impact to absence of EWS while double-knockdown 
of EWS and EWS-FLI1 does not significantly affect the top-ranking EWS-regulated GO terms (columns III 
and IV). Column I – comparison of the original STA-ET-7.2 cell line lacking endogenous EWS to restored 
EWS expression; column II – re-knockdown of EWS vs. expression of EWS and EWS-FLI1 in STA-ET-7.2 
cells; column III – silencing of EWS-FLI1 vs. expression of EWS and EWS-FLI1; column IV – double-
knockdown of EWS/EWS-FLI1 compared to cells expressing EWS and EWS-FLI1. (B) GSEA of the EWS-
KDM. Silencing of EWS-FLI1 has a similar effect compared to knockdown of EWS but is less pronounced 
for repressed genes. Double-knockdown is reminiscent of EWS-silencing although additional silencing of 
EWS-FLI1 attenuates the effect on suppressed GO terms. Column V – EWS knockdown compared to the 
original A673-shEF cell line expressing EWS and EWS-FLI1; column VI – EWS-FLI1 silencing vs. original 
A673-shEF cell line; column VII – EWS/EWS-FLI1 double-knockdown vs. original A673-shEF cell line. 
Significant terms are clustered according to their similarity based on shared genes. EWS and EWS-FLI1 
expression status is indicated by miniature traffic lights. 
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GSEA functional annotation analysis was also performed on EWS-affected genes from the EWS-
KDM (figure 20.B). Similar to the results obtained on the gene level, there was no significant 
overlap between the two cellular models on a functional level. Prominent among the EWS-
activated functional categories were terms connected with DNA metabolism and genotoxic 
stress response, such as “DNA replication”, “DNA repair” and “Response to DNA damage 
stimulus”. EWS-repressed genes from the EWS-KDM were predominantly involved in functions 
related to transmembrane transport. Compared to EWS silencing, knockdown of EWS-FLI1 
affected the top-ranking EWS-repressed GO terms in the same direction but to a lesser extent 
(figure 20.B, columns V and VI). Furthermore, EWS-FLI1 knockdown in A673-shEF added to the 
effect of absent EWS expression (figure 20.B, column VII). 
There is a fundamental difference in the evolution of the ES cell lines which form the basis for 
our two model systems: A673 evolved retaining expression of EWS while STA-ET-7.2 lost 
endogenous EWS expression early in its development. Thus, knockdown of EWS expression 
might activate stress response pathways in A673 cells in contrast to STA-ET-7.2 cells that have 
already adapted to the absence of EWS. Hence, the functional divergence between the two 
cellular models upon EWS silencing can be explained by the distinct evolution of the two utilized 
ES cell lines. 
Taken together, these results suggest that loss of endogenous EWS expression from the STA-ET-
7.2 cell line conforms to - if not increases – the functional effect of EWS-FLI1 on gene expression. 
Regarding the functional relationship between EWS and EWS-FLI1, it is noteworthy that a subset 
of genes with functions in cell signaling could not be rescued from EWS-FLI1 mediated 
repression by silencing of EWS-FLI1 when EWS was not expressed either (figure 20.A, column IV). 
Moreover, GSEA of EWS-regulated genes from the EWS-KDM supported the observed disparity 






3.3.1.3 Determination of transcription start sites by 5’-RACE-PCR 
Based on the finding that EWS interacts with a number of transcription factors (see section 
1.1.3.2) it was implied to be involved in various steps of transcription regulation. EWS has been 
demonstrated to be an associated factor of TFIID and RNAPII (Bertolotti, Melot et al. 1998). 
Thus, we wanted to test whether the effect of EWS on whole transcript levels might be due to 
EWS-mediated differential selection of transcription start sites ultimately resulting in altered 
transcript stability or transcription efficiency. For this purpose, we performed 5’-RACE (rapid 
amplification of cDNA ends) PCR on three of the top ranking genes: leucine-rich repeat-
containing G protein-coupled receptor 5 (LGR5), calcium binding protein 39-like (CAB39L) and 
uncoupling protein 2 (UCP2) (figure 22). However, no remarkable differences concerning the 
transcription start sites of the examined genes could be observed. The obtained PCR products 
mapped in frame within the first 20 base pairs of the transcripts available at the UCSC 
(University of California Santa Cruz) Genome Browser. The maximal difference associated with 
EWS expression were a 12 base pair shorter transcript of LGR5 when EWS was expressed. 
However, we considered the observed minor differences concerning transcript start sites of the 


















Figure 22. EWS does not affect transcription start site selection. (A) Schematic representation of the 
applied RACE-PCR technique. cDNA is ligated to a DNA adapter and subsequently amplified by PCR 
involving one adapter primer and one gene specific primer. In order to increase product specificity, 
nested PCR can be performed with the second adapter primer and a nested gene specific primer. After 
gel elution, PCR products were subjected to sequencing. (B) Three genes have been tested for 
differences in transcription start site depending on the presence/absence of EWS: LGR5, CAB39L and 
UCP2. All transcript start sites detected by 5’RACE PCR were mapped in frame within the first 20 base 
pairs of the sequences available at the UCSC Genome Browser for the respective genes. Differences in 
transcription start site depending on EWS expression ranged between 3 and 12 base pairs. AP1/2 – 
adaptor primer 1/2; GSP1/2 – gene specific primer 1/2; NGSP1/2 – nested gene specific primer 1/2; 
green lollipop – translation start site; red lollipop – translation termination site; (-)-lollipop – 
transcription start site detected in STA-ET-7.2 control (-EWS). (+)-lollipop – transcription start site 
detected in samples with restored EWS expression (+EWS). 
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3.3.2 Analysis of exon composition 
As EWS has also been strongly implicated to play a role in alternative splicing (see section 
1.1.3.3), we analysed the microarray data for variations in exon composition of expressed genes 
and found significant differences in both model systems depending on the presence/absence of 
EWS. However, the impact of EWS-FLI1 knockdown on the exon composition of expressed genes 
was remarkably strong thus obscuring a possible additional or even augmenting effect of EWS-
silencing in the double-knockdown situation. Positive correlation of changed exons upon EWS-











Figure 23. Correlation of exon expression between EWS-FLI1 silencing and double-knockdown of EWS 
and EWS-FLI1. The plot shows  positive correlation implying that most exons that are modulated in one 
direction upon EWS-FLI1 knockdown show the same pattern when EWS is silenced additionally. Hence, 
the effect of disrupted EWS-expression does not alter or augment the exon expression results obtained 
from EWS-FLI knockdown. X-axis – mean logFC of Doxicyclin induced EWS-FLI1 knockdown in A673-
shEF cells (+EWS/-EWS-FLI1) vs. untreated control A673-shEF cells (+EWS/+EWS-FLI1); Y-axis – mean 
logFC of Doxicyclin treated stable clones with silenced EWS expression (KD7s, KD10s) (-EWS/-EWS-FLI1) 
vs. control A673-shEF cells transfected with non-target-shRNA (+EWS/+EWS-FLI1). 
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3.3.2.1 Validation by RT-qPCR 
Skipping of one or several centrally or terminally located exons was observed in 348 genes after 
restoration of EWS expression in STA-ET-7.2 cells and for approximately ten times as many 
(3523) genes for the EWS-KDM for a p-value cutoff of 0.3 and an exon level expression fold 
change of at least twofold. Validation of the results from the in silico analysis was achieved by 
RT-qPCR. For instance, exons 15, 16 and 17 of adenylate kinase 7 (AK7) were downregulated 
upon restoration of EWS expression (figure 24.A and B). This result was confirmed by RT-qPCR 
(figure 24.D) where a clear decrease of AK7 exons 15 - 17 levels was demonstrated for samples 
without EWS expression. The effect of lacking EWS expression could be confirmed by data 
obtained from the EWS-KDM (figure 24.C) which was validated by RT-qPCR as well (figure 24.E). 
Moreover, structural maintenance of chromosome 5 (SMC5) showed reduction of exon 8 upon 
restored EWS expression in STA-ET-7.2 cells (figure 25.A and B). However, this result was not 
supported by data obtained and validated from the stable EWS knockdowns in the EWS-KDM 
(figure 25.C, D and E). Another example, NOD-like receptor C5 (NLRC5) showed higher levels of 
exon 22 upon reconstituted EWS expression (figure 26.A and B) but like SMC5 displayed no 
effect after silencing of EWS from A673-shEF cells (figure 26.C). Again, this could be validated by 
RT-qPCR (figure 26.D and E). 
Taken together, these results support our hypothesis of a EWS-mediated effect on post-
transcriptional gene regulation. However, the observed substantial differences between the 
cellular models largely exclude a specific effect of EWS on the pattern of mRNA isoform 
expression in the ES background. 
Figures 24, 25 and 26. Alterations in exon composition due to modulated EWS expression. Figure 24. 
AK7: exons 15, 16 and 17 are decreased upon restored EWS expression in STA-ET-7.2 cells; when EWS 
is silenced in A673-shEF cells, the expression levels of the same exons are increased. Figure 25. SMC5: 
expression levels of exon 8 are decreased after restoration of EWS expression in STA-ET-7.2 cells; 
however, no inversion of this effect can be observed after knockdown of EWS in A673-shEF cells. 
Figure 26. NLRC5: Exon 22 is expressed at higher levels in the presence of EWS in STA-ET-7.2 cells; 
disruption of EWS expression in A673-shEF cells exerts no detectable effect on exon composition of 
NLRC5. 
(A) Heat maps. Relative expression levels of single exons of the respective genes for samples indicated 
at the bottom of the graph. (B)(C) Exon graphs. Red lines signify samples with EWS expression (+EWS); 
blue lines denote samples without EWS expression (-EWS): (B) EWS-RM - 4 clones with restored EWS 
expression (R37s, R7s, R33r, R34r) vs. two polyclonal control samples without EWS expression; (C) 
EWS-KDM – two clones with stable knockdown of EWS (KD7s, KD10s) vs. two controls (A673-shEF cells 
transfected with empty vector and non-target shRNA, respectively). (D)(E) Validation of microarray 
data by RT-qPCR; red bars indicate experiments with EWS (+EWS), blue bars represent experiments 
without EWS (-EWS); mRNA expression was normalized to GUSB; standard deviations resulting from 
at least two independent experiments, each performed in triplicate.  (D) EWS-RM.  Fold change was 
calculated in comparison to STA-ET-7.2 cells transfected with pCMV Script empty vector. (E) EWS-













3.3.2.2 Overlap between cellular models 
As already mentioned before, significant changes of exon composition upon 
restoration/knockdown of EWS could be detected in both of our cellular models. 348 genes 
changed in exon composition upon restoration of EWS expression in the EWS-RM while 
approximately ten times as many genes responded to knockdown of EWS from A673-shEF cells 
(fold change > 2, adjusted p < 0.3). While the overlap between the two data sets was extremely 
low (2 genes) it was even further reduced to zero when the re-knockdown of EWS from STA-ET-
7.2 cells was considered as well (figure 27). In fact, the before mentioned gene AK7 was the only 
gene with consistently significant changes of transcript structure in STA-ET-7.2 and A673-shEF 
cells upon restored respective silenced EWS expression. Nevertheless, the effect observed for 
AK7 could not be rescued by re-knockdown of EWS in the EWS-RM. In this respect, SMC5 and 
NLRC5 have to be regarded as representative examples for the nature of our data concerning 
the effect of EWS on the splicing pattern in the ES background. 
This result suggests an intrinsic divergence either of the different cellular backgrounds on which 
our models were based or the applied techniques of EWS/EWS-FLI1 gene expression 
modulation. Therefore, no general conclusion concerning an effect of EWS on mRNA-splicing in 








Figure 27. No overlap of differentially expressed exons across experimental systems. Of 
348 genes affected in exon composition by reconstituted EWS expression in STA-ET-7.2 cells 
only 4 genes displayed reversion of the observed effect after re-knockdown of EWS. 
Additionally, of 3523 genes with altered exon composition upon silencing of EWS in A673-
shEF cells only 3 genes were shared with the EWS-RM, none of which belonged to the 4 
genes from the intersection. Red circles ≙ EWS-RM (EWS-restoration model/STA-ET-7.2 cell 
line); blue circles ≙ EWS-KDM (EWS-knockdown model/A673-shEF cell line); exon fold 




3.3.2.3 Applicability of data obtained from different cell lines 
Recently published data adds to the evidence for a role of EWS in post-transcriptional gene 
regulation (Paronetto, Minana et al. 2011). Depletion of EWS was found to be causal for 
alternative splicing of genes involved in DNA repair and genotoxic stress signaling in the HeLa 
background. Paronetto and colleagues achieved transient silencing of EWS upon transfection of 
siRNA. The resulting samples were analysed on splicing sensitive microarrays involving exon-
centric as well as exon-junction spanning probes. The applied microarray platform was designed 
to specifically investigate 1804 alternative splicing events in 482 genes which encode for 
proteins involved in RNA processing and cancer (Munoz, Perez Santangelo et al. 2009). 
Knockdown of EWS was reported to cause transcript level changes higher than 1.3-fold in 9 
genes and 39 alternative splicing events in 31 genes. For their successive studies Paronetto and 
colleagues selected three genes from their microarray data for validation: CHEK2, MAP4K2 and 
ABL1. Knockdown of EWS produced higher levels of exon 2 skipping in the checkpoint kinase 
CHEK2 and increased skipping of exon 9 from the germinal center kinase MAP4K2 mRNA. 
Furthermore, knockdown of EWS was reported to affect 5’splice donor selection in exon 3 of the 
nonreceptor tyrosine kinase ABL1.  As a control, the non-regulated exon 2 of the gene QKI was 
used.  
Since we detected substantial differences regarding the effect of EWS on exon composition 
between two models established in different ES cell lines, we were eager to know to what extent 
data from HeLa cervical carcinoma cells could be applied to our own cellular models. To this end, 
we compared the results of Paronetto and colleagues for the genes CHEK2, MAP4K2 and ABL1 
with our own data obtained from the EWS-RM. By in silico analysis of whole genome expression 
data on Hu-Ex1.0 stv2 arrays, we detected slight, non-significant changes in the respective exons 
of CHEK2 and MAP4K2 but not ABL1. This is most likely due to the applied Affymetrix Hu-Ex1.0 
stv2 chips not being designed for the optimal detection of alterations regarding the splice 
donor/acceptor site. To confirm our in silico observation we performed SYBRgreen RT-qPCR on 
the samples from the EWS-RM. The results could be validated for CHEK2, MAP4K2 and the 
control QKI (figure 28.A, B and C). The PCR results obtained from ABL1 were not conclusive (data 
not shown). Accordingly, the data of Paronetto et al. is consistent with our finding that EWS 
affects transcript levels and exon composition. Resulting from fundamental differences 
concerning the experimental setup (one vs. two cellular models, transient silencing vs. 
reconstituted expression and stable silencing of EWS, microarrays covering a specific gene set 
involving exon and exon-junction probes vs. microarrays covering the whole genome by exon-
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centric probes only) little overlap between the data of the two studies was expected. 
Nevertheless, EWS-dependent splice-isoforms from the HeLa system could be confirmed in the 
ES background.  
Figure 28. Applicability of microarray data generated in the HeLa background to the ES background. 
All three genes identified by Paronetto and colleagues as being affected in exon composition by the 
absence of EWS were tested in our own model systems for general applicability of the reported results. 
Results for ABL1 were not conclusive and are not shown. The uppermost panels show schematic 
representations of the examined exons of interest. Middle panels exhibit SYBRgreen PCR results 
obtained from samples derived from STA-ET-7.2 cells with restored EWS expression. The lowermost 
panels represent results obtained after re-knockdown of EWS. For each examined exon or exon-exon-
junction a mean of clones was calculated that was normalized to the respective control (first column of 
each panel: STA-ET-7.2 cells transfected with pCMV Script empty vector or STA-ET-7.2 clones with 
restored EWS expression transfected with non-target shRNA). Red bars indicate experiments with EWS 
expression (+EWS), blue bars represent experiments without EWS expression (-EWS); standard 
deviations result from two independent experiments, each performed in triplicate. (A) Increased levels 
of CHEK2 exon 2 were detected in cells with reconstituted EWS expression resulting in decreased PCR 
product from probes spanning exons 1-3. Silencing of EWS lead to enhanced skipping of exon 2 thus 
increasing PCR product yield due to smaller amplicon size. (B) Expression of EWS resulted in elevated 
levels of MAP4K2 exon 9, while knockdown of EWS lead to increased skipping of MAP4K2 exon 9. (C) 
QKI served as negative control in the experimental setting and exon composition was therefore not 


































The oncogenic fusion protein EWS-FLI1 is specific to ES and has been shown to be the key 
determinant of ES oncogenesis and progression (Bailly, Bosselut et al. 1994; Chansky, 
Barahmand-Pour et al. 2004; Ordonez, Osuna et al. 2009; Kovar 2010) either by its role as potent 
transcriptional modulator (for references see table 2) or by various functions in post-
transcriptional processing (Yang, Chansky et al. 2000; Chansky, Hu et al. 2001; Knoop and Baker 
2001; Sanchez, Bittencourt et al. 2008). Additionally, it was proposed that EWS-FLI1 might as 
well interfere with other, transcription-independent tumor suppressor pathways (Hu, Zielinska-
Kwiatkowska et al. 2008). However, the mechanisms behind EWS-FLI1 mediated carcinogenesis 
are only partially understood. Since EWS-FLI1 was found to associate with its germline 
counterpart EWS (Spahn, Siligan et al. 2003), it was suggested that this interaction interferes to 
some extent with normal EWS function. Hence, the project reported in this thesis is based on the 
hypothesis that the functional interference/interaction between EWS and EWS-FLI1 contributes 
to ES tumorigenesis. 
To date, the molecular functions of FET family proteins in general, and of EWS in particular, are 
not very well defined. The work represented in this thesis deals with the role of EWS on 
transcription regulation and splicing in the ES background and the possible effects of a functional 
interference of EWS-FLI1. To this end, two different cellular models enabling for the modulated 
expression of EWS and/or EWS-FLI1 have been established: the EWS-RM based on the STA-ET-
7.2 ES cell line and the EWS-KDM utilizing A673-shEF ES cells. Since the EWS-RM allowed for an 
internal validation by re-knockdown of reconstituted EWS expression it was selected as 
predominant cellular model. The EWS-KDM was intended to serve validation purposes for 
results gained from the EWS-RM. However, the overlap between the microarray datasets 
concerning either alternative exon composition or differential gene expression obtained from 
the two models was surprisingly small. GSEA of the top-ranking genes from both cellular models 
confirmed the observed disparity on the gene level also on a functional level. Variations in the 
evolution of the two ES cell lines with and without endogenous EWS, respectively, could very 
likely account for the observed differences. For instance, GO terms related to “stress response” 
were prominent in the EWS-KDM but not in the EWS-RM. Indeed, the activation of stress 
response pathways upon depletion of a multifunctional protein, such as EWS, is plausible in 
context of a cell line that is not adapted to the absence of this gene. Furthermore, different 
experimental backgrounds of the two model systems might also account for the lack of shared 
gene/ exon expression data. The functional relationship between EWS and its oncogenic 
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derivative is probably more complex than initially postulated, most likely involving additional 
factors. Thus, the comparison of two different “on/off”-systems, one featuring stable over-
expression and transient re-knockdown (EWS-RM) the other endogenous expression and stable 
knockdown of EWS (EWS-KDM), both in combination with transient silencing of EWS-FLI1, may 
not be sufficient to recapitulate the interplay between EWS and EWS-FLI1. 
Samples from both cellular models were subjected to microarray analysis employing Affymetrix 
Hu-Ex stv2 chips. Utilizing only exon-centric probes, this microarray platform allows for the 
analysis of two aspects of gene regulation: differential exon composition and expression level 
variations of whole transcripts. However, due to the absence of exon-junction spanning probes, 
this array platform is not suited for the detection of altered splice donor/acceptor sites. 
Nevertheless, the choice of the cheaper Affymetrix arrays allowed for the analysis of a greater 
number of samples on a whole genome scale in comparison to the analysis performed by 
Paronetto et al. which covered only a limited gene set (Paronetto, Minana et al. 2011). 
The microarray data obtained from the cellular model systems was analysed regarding different 
aspects of EWS function and a possible involvement of EWS-FLI1. Concerning a combined effect 
of EWS and EWS-FLI1, the differentially expressed genes shared by the two model systems could 
be classified according to two different models of possible functional interference/interaction 
between EWS and the fusion protein: First, the “functional competition model” includes genes 
directly regulated by EWS and EWS-FLI1 but in opposite directions. Second, the “functional 
interference model” comprises genes whose expression is directly affected by EWS which is in 
turn inhibited by the fusion protein. Hence, the “functional interference model” is in line with 
the functional relationship between EWS and EWS-FLI1 which also represents the hypothetic 
basis of this study. 
Concerning the EWS/EWS-FLI1-dependent regulation patterns associated with the “functional 
competition model”, our observations were supported by functional annotation of the involved 
genes. The top enriched GO terms identified by gene set enrichment analysis (GSEA) were highly 
reminiscent of previously suggested functions for EWS such as “RNA splicing” and “RNA 
processing” for EWS-repressed genes and “cell signalling” for EWS-activated genes. This strongly 
supports our hypothesis of an EWS-involvement in transcription regulation. 
Furthermore, the analysis of the microarray data yielded valuable information concerning EWS-
specific effects on gene expression and exon composition. LGR5, which is known to be a marker 
of adult stem cells (Haegebarth and Clevers 2009), is one of the genes described in the 
“functional competition model”. Hence, its activation was detected in presence of EWS 
expression and its repression upon absence of EWS expression as well as re-silencing of EWS in 
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the EWS-RM. These results were further supported by unpublished data from Elizabeth R. 
Lawlor’s lab (University of Michigan, MI, USA) concerning a correlation of EWS and LGR5 
expression in human neural crest stem cells. Accordingly, expression of LGR5 decreases with 
progressive differentiation, as well as EWS expression (personal communication). This 
observation is supported by the earlier results of Andersson et al. that expression of all FET 
proteins was decreased in differentiating human embryonic stem cells and during induced 
differentiation of neuroblastoma cells. Furthermore, it was reported that no expression of FET 
proteins could be detected in terminally differentiated melanocytes and cardiac muscle cells 
(Andersson, Stahlberg et al. 2008). Thus, our findings of EWS expression correlating with 
increased LGR5 expression are in line with previous observations of a positive effect of EWS on 
the expression of the stem cell markers HNF-4 (Araya, Hirota et al. 2003) and OCT-4 (Lee, Rhee 
et al. 2005) which very likely contributes to the maintenance of the undifferentiated state 
characteristic for ES cells. Together, our results further add to the evidence of EWS being 
involved in transcription regulation of genes. The molecular mechanism of this function, 
however, remains to be elucidated. 
Various factors and mechanisms have been reported to account for transcriptional modulations 
such as alternative transcription start site selection (Sandelin, Carninci et al. 2007; Thorsen, 
Schepeler et al. 2011; Lenhard, Sandelin et al. 2012). Indeed, EWS has been proposed to partake 
in transcription start site recognition (Hume, Sasmono et al. 2008). Consequently, we wanted to 
test whether EWS-dependent differential selection of transcription start sites accounts for the 
detected differences in gene expression levels of single genes probably by causing variant 
transcript stability or transcription efficiency. However, results obtained from 5’ RACE-PCR 
experiments did not support the idea of EWS-dependent differential transcription start site 
selection as a potential cause of altered transcript stability to account for the observed 
differential RNA expression effect for the selected candidate genes. 
Significant differences in exon composition of genes were detected in each of the two applied 
cellular systems which could also be validated by RT-qPCR. However, almost no overlapping data 
could be obtained from the two different models. Additionally, the impact of EWS-FLI1 silencing 
on alternative exon composition was so strong that the effect of additional EWS knockdown 
could not be assessed. Thus, no general conclusion could be drawn concerning the combined 
involvement of EWS and EWS-FLI1 in alternative splicing in the ES background. The 
establishment of an improved cellular model enabling for fine-tuning adjustment of EWS and 
EWS-FLI1 expression as well as microarray analysis focusing on alternative splicing by involving 
exon-junction spanning probes might help to solve this question. Since very recently published 
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results attained from a HeLa model are strongly in favour of a role for EWS in alternative splicing 
(Paronetto, Minana et al. 2011), we cross-checked these data with our own cellular models. For 
two of the three tested genes of the Paronetto-study we could reproduce the reported results 
involving SYBRgreen RT-qPCR and the published primer sequences. However, the significance of 
the results was rather low due to high clonal variations. Nevertheless, any consistency between 
the two studies is noteworthy considering the fundamental differences regarding cellular 
background, experimental setup, applied microarray platform and analysis. 
Taken together, the results concerning differential exon composition were not conclusive 
concerning the effect of EWS on RNA processing in the ES background. In case of this particular 
study, independent evolution of the applied ES cell lines may explain the divergence observed in 
data regarding exon composition: On the one hand, A673 cells retained EWS expression 
throughout tumorigenesis. Loss of EWS from STA-ET-7.2 tumor cells, on the other hand, most 
probably induced these cells to compensate for this deficit possibly by an expansion of EWS-FLI1 
function. Nevertheless, it was shown that the cellular background exerts great influence on the 
results of a study. Similar observations have been reported for the interpretation of EWS-FLI1 
target gene studies in the ES background (Kovar 2010). 
In order to investigate EWS-specific effects on the ES cell phenotype, two different functional 
assays were performed: proliferation assays and soft agar colony formation assays. 
Reconstituted EWS expression in the EWS-RM conferred no advantage concerning anchorage-
dependent growth in the proliferation assay setting which is supported by earlier findings of 
Kovar et al. (Kovar, Jug et al. 2001). Anchorage-independent growth, on the other hand, was 
significantly improved by restoration of EWS expression to STA-ET-7.2 cells as could be observed 
in soft agar colony formation assays. EWS-specificity was confirmed by the reversion of this 
effect upon re-knockdown of EWS from STA-ET-7.2 cells. It is generally known that tissue culture 
conditions involving anchorage-dependent growth do not recapitulate the physiologic conditions 
of human tissue. However, morphologic and histochemical analysis showed, that cells grown in 
soft agar colony formation assays exhibit the same characteristics as original tumor cells 
(Hamburger, Salmon et al. 1978). Hence, the results obtained from the soft agar colony 
formation assays stress the relevance of EWS expression in ES tumorigenesis by enhancing 
tumor cell growth. 
In summary, the results described in this thesis are consistent with the current scientific 
evidence for an involvement of EWS in transcriptional and post-transcriptional regulation. The 
differences observed in two different cell line models emphasize the necessity to consider the 
cellular background for the interpretation of scientific results. Significant effects of EWS on exon 
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composition of transcripts were detected in both cellular model systems. However, the resulting 
data could not be merged to draw a general conclusion. From the overlapping data of the two 
cellular models concerning EWS-dependent transcriptional regulation two types of genes could 
be defined matching two different models of functional relationship between EWS and EWS-
FLI1. This may point to a probably more subtle, indirect commitment of EWS in the splicing 
process compared to its role in transcription regulation. Taken together, this suggests a complex 
functional relationship between EWS and EWS-FLI1, probably involving additional factors, which 
cannot be reproduced by overexpression and/or silencing of EWS and/or EWS-FLI1 alone but 

























PBS-T and TBS-T 
Add 0,1% Tween 20 to above mentioned PBS and TBS, respectively 
 
5.1.1.2 SDS-PAGE buffers 
2x Sample Buffer 
20% (v/v) glycerol 
6% ß-mercaptoethanol 
3% SDS 










20% methanol per 1000 ml 
Ponceau Staining Solution (10x) 
2g Ponceau S 
30g trichloroacetic acid 




5.1.1.3 Protein extraction buffers 
Hunt Buffer 
500mM NaCl 
50mM Tris-Cl pH 8,0 
1mM EDTA 
0,5% NP-40 




5.1.2.1 Bacterial media 
Luria Broth (LB) Medium 
1% NaCl 
1% Tryptone (Oxoid, Hampshire, UK) 
0,5% yeast extract (Oxoid, Hampshire, UK) 
optional 2% bacteriological agar (Oxoid, Hampshire, UK) for plates 
sterilize by autoclaving 
5.1.2.2 Cell culture media 
RPMI 1640, GlutaMAX™-I (GIBCO™, Life Technologies, Carlsbad, CA) 
2g/L D-Glucose, 1mg/L Glutathione (reduced) 
DMEM (Dulbecco’s Modified Eagle Medium), high glucose, GlutaMAX™-I, pyruvate (GIBCO™, 
Life Technologies, Carlsbad, CA) 
4.5g/L D-Glucose, 110mg/L Sodium Pyruvate. 
OPTI-MEM I (GIBCO™, Life Technologies, Carlsbad, CA) 
2xRPMI 
2,086g RPMI 1640 Powder (GIBCO™, Life Technologies, Carlsbad, CA) and 0,2g NaHCO3 
were dissolved in 80ml ddH2O. pH was set to 7,1-7,2 with 6M HCl and ddH2O was added 
to a final volume of 100ml. 2xRPMI was filter sterilized with a 0,20 Micron disposable 
filter (Iwaki™, AGC, Chiyoda, Japan) and stored at 4°C until use. 
 
5.1.3 Antibiotics 
G418 Sulphate (50mg/ml) (PAA, Pasching, Austria), endconcentration 500μg/ml 
Doxicyclin Hyclate (SIGMA-Aldrich, Saint Louis, MI), endconcentration 1μg/ml 
Blasticidin (InvivoGen, San Diego, CA), endconcentration 2μg/ml 
Zeocin (InvivoGen, San Diego, CA), endconcentration 50μg/ml 







All restriction endonucleases and corresponding buffers were purchased from New 






Calf intestine alkaline phosphatase (CIP) (NEB, Ipswich, MA) 
Ligation 





 α-EWS: Rabbit Anti-EWS 139/2 (by C. Denny) 
 α-FLI1: Rabbit Anti-FLI1 (PAb RB-9295-P) (Eubio, Vienna, Austria) 
 α-β-Actin: MS mAb to beta Actin (mAbcam 8226) 
Secondary antibodies 
 α-rabbit: Goat Anti-Rabbit IgG (H+L) DyLight™ 800 conjugated (Thermo 
Fisher Scientific, Rockford, IL) 
 α-mouse: Goat Anti-Mouse IgG (H+L) DyLight™ 800 conjugated (Thermo 
Fisher Scientific, Rockford, IL) 
 
5.1.6 Plasmids 
pCMV Script Vector (Agilent Technologies, Santa Clara, CA) is a mammalian expression vector, 
containing the cytomegalovirus (CMV) immediate early promoter, the kanamycin-
resistance gene for bacterial selection and the neomycin-resistance gene for mammalian 
selection with G418 which is driven by the SV40 early promoter. 
pSUPER.retro.puro (OligoEngine, Seattle, WA) is a mammalian expression vector that directs 
the intracellular synthesis of siRNA- or shRNA-like transcripts under control of the 
polymerase III H1-RNA gene promoter. Furthermore, the vector contains the puromycin 
and ampicillin-resistance gene, the 3’delta LTR and the 5’ LTR. 
pGEM-T Easy Vector System (Promega, Madison, WI) pGEM-T Easy is a linearized vector with 
a single terminal 3’-thymidine overhang at both ends. These T-overhangs prevent the 
vector from recircularization and facilitate cloning of PCR products. 
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pLKO.1-puro (SIGMA-Aldrich, Saint Louis, MI) is a lentiviral plasmid vector for intracellular 
expression of shRNA-transcripts. Ampicillin and puromycin antibiotic resistance allow for 






3’UTR: sense TGCATTGACTACCAGATTTAT 
Exon 11: sense GTACAAGGATTAAATGACA 
targeting EWS-FLI1 
EFsi22: sense AGCTACGGGCAGCAGAGTTCACTGCTGGCCTAT 




EWS  forward CAGCCAAGCTCCAAGTCAATATAG (Tm 61,4°C) 
  reverse TCATGCCTCCACGATCAAAT (Tm 61,4°C) 
EWS-FLI1 forward TCCTACAGCCAAGCTCCAAGTC (Tm 62,1°C) 
  reverse ACTCCCCGTTGGTCCCCTCC (Tm 65,5°C) 
β-Actin  forward GCCGGGAAATCGTGCGTG (Tm 60,5°C) 
  reverse GGGTACATGGTGGTGCCG (Tm 60,5°C) 
E2F1  forward  TGCTGCTCTTCGCCACACCG (Tm 62°C) 
  reverse ATGCGCCGCTTCTGCACCTT (Tm 62°C) 
TGFbR2  forward TTGCTCACCTCCACAGTGATC (Tm 64°C) 
  reverse GAGCCGTCTTCAGGAATCTTC (Tm 64°C) 
VEGF  forward CCTCCGAAACCATGAACTTT (Tm 58°C) 
  reverse AGAGATCTGGTTCCCGAAAC (Tm 60°C) 
RT-qPCR 
AK7  forward TGGGAGGAGTGGAATAAACG 
  reverse CGTTGCAACATTCATTCAGG 
  probe TGGAGGAAGTGAAAAGAGAAGAAAGAGAAT 
SMC5  forward ATTTGGAGGCTCGAATCAA 
  reverse GCCTGCTGAAGTTCCTCAA 
  probe GAAAAGGCAACAGATATTAAGGAGGCATC 
GUS  forward GAAAATATGTGGTTGGAGAGCTCATT 
  reverse CCGAGTGAAGATCCCCTTTTT 




AP1  CCATCCTAATACGACTCACTATAGGGC 
AP2  ACTCACTATAGGGCTCGAGCGGC 
[sequences of AP1 and AP2 taken from Marathon cDNA Amplification kit 
manual (Clontech, Mountain View, CA)] 
LGR5   GSP1 CTCTCCAGGTTTGCAGTTCCAGTT 
  GSP2 GAGGCACCATTCAGAGTCAGTGTTC 
  GSP3 AAGTCTCTAGGCTGTGGAGCCCATC 
  GSP4 GGTGTATTTTGTTCAGGGCCAAGG 
  GSP5 CAGAGCTTCTGTGGGTACGTGTCTT 
  GSP6 TAGGTAGGAGGTGAAGACGCTGAGG 
CAB39L  GSP1 CCCACAACGTAAGGCAATCTGTG 
  GSP2 CTGCTTCTGTTGGGGGTTCTTTCT 
  GSP3 TCCGAGTGCCTATCTGTCTTCTCAAG 
  GSP4 GTAGACACATGGTGAGGTGCTGAAGA 
  GSP5 AGCGTGGCAGAGAAAAGAGTTTCC 
UCP2  GSP1 CATTGACGGTGCTTTGGTATCTCC 
  GSP2 TGCTCAGAGCCCTTGGTGTAGAAC 
  GSP3 CCCCTGACTTTCTCCTTGGATCTGT 
  GSP4 AGCTTCTCTAAAGGTGTCCCGTTCTTC 
  GSP5 GTGGGAGACGAAACACCTAATGGTC 
SYBRgreen-qPCR 
Primer sequences taken from supplementary material of Paronetto et al. (Paronetto, 
Minana et al. 2011) 
CHEK2  ex6-F GGTGCCTGTGGAGAGGTAAA 
  ex6-R GCCTCTCTTGCTGAACCAAT 
  ex1-F GTTTAGCGCCACTCTGCTG 
  ex2-R CGAGACATCACGACCGCGTG 
  ex2-F GACCAAGAACCTGAGGACCA 
  ex3-R TCATTCACACATTCAAGATTGG 
  ex3-R CATTCACACATTCGCGTGAG 
  ex2-Fbis CTCTGGGACACTGAGCTCCT 
  ex2-Rbis TGGTCCTCAGGTTCTTGGTC 
MAP4K2 ex12-F ACCCGTTCACGACTCAGC 
  ex12-R CTCCAGCTCACAGTCCTCAG 
  ex9-F AGCGCAAAGGTGGCTACAAT 
  ex9-R GGGTGCAGGTGGAACAGA 
  ex8-9-F  TTGGGACTCCCTACTGGATG 
  ex9-10-R CATGAGCATCAGGGCCCTCATG 
  ex8-F CTGACTTTGGGGTGTCAGG 




QKI  ex4-F GGAGCAAAATAGAGGCAAGC 
  ex4-R TCTGAGCATCTTCCACAGTGA 
  ex1-F CCACCCCAGATTACCTGATG 
  ex1-2-R GCTAATTTCTTCGTCCAGCA 
  ex1-3-R CAAAATTAAACTTCGTCCAGCA 
  ex2-F GGAGTGCAGAATTGCCTGAT 
  ex2-3-R CCCAACAAAATTAAAATCTGGGTA 
ABL1  ex2-F CGGCCAGTAGCATCTGACTT 
  ex2-R GGTTGGGGTCATTTTCACTG 
  ex3-F ATCACAATGGGGAATGGTGT 
  ex3-R CTTGCCATCAGAAGCAGTGT 
  ex3-4-R TCGGAGGAGACGTAGACAC 
 
5.1.9 Bacterial Strains 
JM109 competent E.coli; genotype: endA1, recA1, gyrA96, thi, hsdR17 (rk–, mk+), relA1, 
supE44, Δ(lac-proAB), [F′, traD36, proAB, laqIqZΔM15] (Promega, Madison, WI) 
 
5.1.10 Cell lines 
STA-ET-7.2: Ewing’s Sarcoma cell line established by the laboratory of Heinrich Kovar, 
Children’s Cancer Research Institute, Vienna, Austria. Normal chromosome 22 was lost 
while the chimeric chromosome was duplicated. Thus, endogenous expression of EWS 
was lost and only EWS-FLI1 type 2 is expressed (Kovar, Jug et al. 2001). 
A673-shEF: Ewing’s Sarcoma cell line established by the laboratory of Javier Alonso, Unidad 
de Tumores Solidos Infantiles, Instituto de Salud Carlos III, Majahonda, Spain. EWS-FLI1 
type 1 is expressed. This cell line was stably transfected with a doxicyclin-inducible 
shRNA expression-construct targeting EWS-FLI1 type 1 (Carrillo, Garcia-Aragoncillo et al. 
2007). 
A673-shGFP: Ewing’s Sarcoma cell line established by the laboratory of Javier Alonso, Unidad 
de Tumores Solidos Infantiles, Instituto de Salud Carlos III, Majahonda, Spain, as a 








5.2.1 Plasmid Mini Prep 
For plasmid mini preparations the Plasmid Mini Kit (QIAGEN, Hilden, Germany) was used 
according to the manufacturer’s instructions. 
 
5.2.2 Plasmid Maxi Prep 
For endotoxin-free plasmid maxi preparations EndoFree Plasmid Maxi Kit (QIAGEN, Hilden, 
Germany) was used according to the manufacturer’s instructions. 
 
5.2.3 RNA extraction 
For extraction of whole RNA from mammalian tissue culture cells RNeasy Mini Kit (QIAGEN, 
Hilden, Germany) was used according to the manufacturer’s instructions. 
 
5.2.4 Bacterial Transformation 
JM109 competent bacteria were thawed on ice and incubated with the plasmid of interest 
for 10 minutes on ice. 200μl LB medium were added after heat shock (42°C for 1 minute) 
followed by incubation at 37°C for 20 minutes. Finally, bacteria were plated on LB plates 
containing 0,1mg/ml ampicillin and incubated over night at 37°C. 
 
5.2.5 Cell Culture Techniques 
5.2.5.1 General techniques 
Cells were kept adherently in cell culture dishes (petridishes or flasks by Iwaki™, AGC, 
Chiyoda, Japan and SPL Lifesciences, Pocheon City, South Korea, respectively). STA-ET-
7.2 cells were kept in RPMI 1640 + GlutaMAX™-I (GIBCO™, Life Technologies, Carlsbad, 
CA; see also section 5.1.2.2.1) and A673-shEF were kept in DMEM (Dulbecco’s Modified 
Eagle Medium), high glucose + GlutaMAX™-I (GIBCO™, Life Technologies, Carlsbad, CA; 
see also section 5.1.2.2.2) with Blasticidin and Zeocin, respectively. Both media were 
supplied with 10% Fetal Bovine Serum (FBS) Gold (PAA, Pasching, Austria) and 
Penicillin/Streptomycin (100x) (PAA, Pasching, Austria). For STA-ET-7.2 cells cell culture 
dishes were coated with Fibronectin pure (Roche Diagnostics, Mannheim, Germany). To 
remove the cells from the cell culture dish they were washed once with DPBS (PAA, 
Pasching, Austria), treated for approximately 1-4 minutes with Accutase or Trypsin-EDTA 




5.2.5.2 Cell transfection and selection 
Cells were seeded 24 hours prior to transfection at a density of approximately 30% in a 
75ccm cell culture flask (SPL Lifesciences, Pocheon City, South Korea). The normal 
growth medium was aspirated, cells were washed once with OPTI-MEM and starved in 
OPTI-MEM for approximately 1 hour prior to transfection. In the meantime, transfection 
mixes A and B were prepared where mix A consisted of 625μl OPTI-MEM, 4μg DNA, and 
20μl Plus™ Reagent (Invitrogen, Carlsbad, CA) and mix B contained 625μl OPTI-MEM and 
30μl Lipofectamine™ LTX (Invitrogen, Carlsbad, CA). Both mixes were vortexed 
thoroughly and incubated for 15 minutes at RT. Mixes A and B were combined and again 
incubated at RT for 15 minutes after which 6 ml of OPTI-MEM were added. OPTI-MEM 
was aspirated and the cells were incubated with the transfection mix for 3,5 hours at 
37°C/ 5% CO2. The transfection mix was aspirated, 10 ml of growth medium without any 
antibiotics were added and the cells recovered for 24 hours at 37°C/ 5%CO2. Then, 
growth medium was exchanged for selection medium containing the required antibiotics 
and incubated for 24 or 72 hours before proceeding with Soft Agar Assay or harvesting, 
respectively. 
 
5.2.5.3 Proliferation Assay 
75000 cells were seeded per well of a cell culture 6 well-plate (Iwaki™, AGC, Chiyoda, 
Japan) in triplicate. Cells were harvested after 24, 48, 72 and 96 hours, respectively, and 
counted with a Bürker-Türk chamber. 
 
5.2.5.4 Soft Agar Assay 
1.4% Difco™ Agar Noble (BD, Franklin Lakes, NJ) in ddH2O was boiled in a microwave and 
equilibrated to 45-50°C in a waterbath. In the meanwhile, 2xRPMI and FBS were 
equilibrated to 37°C in a waterbath. For the underlayer 675μl 2xRPMI, 150μl FBS, 15μl 
Penicillin/Streptomycin (and other antibiotic if required) are mixed with 675μl 1,4% agar 
per well of a 6-well plate. Temperature of the agar mix must not be too low and the 
whole bottom of the well must be equally covered. Store underlayer in the incubator 
until the cell layer is ready (approximately 15 minutes). For the cell layer mix A (15000 
cells in 2,5ml RPMI 1640) and mix B (1,25ml 2xRPMI, antibiotics and 1,25ml 1,4% agar) 
are prepared in separate tubes. Mix A and mix B are combined and pipetted onto 
underlayer. Leave in the laminar at RT to polymerize for 15 minutes and add upper layer 
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(same procedure as for the underlayer). Incubate at 37°C/ 5% CO2 for 7-21 days and feed 
the cells every 3rd day by adding 2 drops of culture RPMI 1640. 
 
5.2.6 Protein Analysis 
5.2.6.1 Protein extracts 
Crude extract 
Cells were harvested and counted using a Z2 Coulter® Particle Count and Size Analyzer 
(Beckman Coulter™, Krefeld, Germany). After washing twice with PBS the cell pellet was 
dissolved in equal amounts of PBS and 2x Sample Buffer resulting in a concentration of 
30000cells/μl. The extract was boiled at 96°C for 7 minutes and spun down at 13000rpm 
for 15 minutes. 
Hunt extract 
Cells were harvested, counted and washed as described above. The cell pellet was 
dissolved in Hunt buffer to a concentration of 60000cell/μl. The cells were disrupted by 
two cycles of drop-freeze in liquid nitrogen followed by thawing on RT and on ice, 
respectively. The extract was spun down at 13000rpm for 15 minutes, the supernatant 
was transferred to a fresh tube and diluted 1:1 with 2x Sample Buffer. Finally, the extract 
was boiled at 96°C for 7 minutes and spun down at 13000rpm for 15 minutes. 
5.2.6.2 SDS-PAGE and Immunoblotting 
For immunoblot analysis, total protein extracts were resolved by SDS-PAGE and 
processed for Western Blotting essentially as described by Laemmli (Laemmli 1970). 
Electrophoretic transfer of proteins from gel to nitrocellulose membranes was either 
done at 400mA for 1 hour under constant cooling in an ice box or at 22mA over night at 
4°C. Filters were stained with PonceauS to check for equality of loading and transfer 
efficiency and blocked for 1 hour at RT with 1x blocking reagent (Roche Diagnostics, 
Mannheim, Germany). Incubation with primary antibody in 0,5x blocking reagent over 
night at 4°C was followed by incubation with secondary antibody in LI-COR Blocking 
Buffer (LI-COR Biosciences, Lincoln, NE) for 1 hour at RT. Signals were detected with a 





5.2.7 Affymetrix Exon Array and Computational Analysis 
Exon array (Hu-Ex1.0 stv2, Affymetrix, Santa Clara, CA) analysis was performed on total 
RNA in collaboration with the Gene Expression Profiling Unit of the Medical University 
Innsbruck. cRNA target synthesis and GeneChip® processing were performed according 
to standard protocols (Affymetrix, Inc., Santa Clara, CA). CEL files were analyzed in R 
statistical environment using Bioconductor packages (Gentleman, Carey et al. 2004). The 
“aroma-affymetrix” package was used to perform exon array specific analyses 
(Bengtsson, Simpson et al. 2008). Only “core” probesets were analyzed using the custom 
cdf provided by the aroma-affymetrix project (http://aroma-project.org/node/29). In the 
following analysis also “cross-hybridizing” probes and probesets were excluded (as 
indicated in the NetAffx Annotation Files available from affymetrix.com). The analysis 
pipeline followed essentially the vignette for FIRMA analysis available from: 
http://aroma-project.org/vignettes/FIRMA-HumanExonArrayAnalysis. In brief, CEL files 
were read into R, background corrected, summarized by the RMA algorithm and quantile 
normalized (Irizarry, Bolstad et al. 2003; Bengtsson, Simpson et al. 2008). Subsequently 
exon-level and transcript-level expression estimates were extracted. The FIRMA 
algorithm was applied to indentify exons that deviate from RMA estimates of the 
transcripts (Purdom, Simpson et al. 2008) and FRIMA scores were compared for each 
exon between experimental treatments using a moderated t-test from the R package 
limma (Wettenhall and Smyth 2004). Limma was also used to detect differences 
between experimental groups in whole transcript levels and in exon levels separately. To 
preclude erroneous results due to very low hybridization signals these probesets were 
filtered out before analysis (quantile < 0.4). 
 
 
5.2.8 PCR Techniques 
RT-PCR 
Total RNA was transcribed into cDNA using random hexamer primers (Promega, 
Madison, WI) and M-MLV Reverse Transcriptase (Promega, Madison, WI) according to 
manufacturer’s instructions. PCR reactions were set up with DyNAzyme™ II DNA 
Polymerase (Finnzymes, Thermo Fisher Scientific, Rockford, IL) and run in a Dyad Disciple 






Total RNA was transcribed into cDNA and ligated to a DNA-adaptor using the Marathon 
cDNA Amplification Kit (Clontech, Mountain View, CA) according to the manufacturer’s 
instructions. 5’RACE-PCR reactions were performed in a Dyad Disciple Thermal Cycler 




For quantitative SYBRgreen PCRs the Maxima® SYBR Green/ ROX qPCR Master Mix (2x) 
(Fermentas, Thermo Fisher Scientific, Rockford, IL) was used according to manufacturer’s 
instructions. The reactions were run in a 7500 Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA) and analysed with the corresponding software. 
 
RT-qPCR 
Total RNA was transcribed into cDNA as described in 2.8.1. Quantitative RT-PCR 
reactions were set up using TaqMan® Gene Expression Master Mix (2x) (Applied 
Biosystems, Foster City, CA) according to the manufacturer’s instructions and run in a 
7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) and analysed with 
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